<?xml version="1.0" encoding="UTF-8"?>
<response>
<lst name="responseHeader"><int name="status">0</int><int name="QTime">6</int><lst name="params"><str name="q">myeloma</str></lst></lst><result name="response" numFound="553" start="0"><doc><arr name="city"><str>Minneapolis</str></arr><arr name="conditions"><str>Multiple Myeloma</str><str>Multiple Myeloma and Plasma Cell Neoplasm</str><str>Multiple Myeloma And Immunoproliferative Neoplasms</str><str>Mult Myelm W/O Remission</str><str>Mult Myelm W Remission</str><str>Multiple Myeloma Stage I</str><str>Multiple Myeloma Stage Ii</str><str>Multiple Myeloma Stage Iii</str><str>Fgfr3/Igh Fusion</str><str>Increased Risk For Multiple Myeloma</str><str>Lig4, Ala3val</str><str>Lig4, Thr9ile</str><str>m protein, multiple myeloma</str><str>prevention of multiple myeloma</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; stage ii or higher (for use in a medicare-approved demonstration project)</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; extent of disease unknown, </str><str>whsc1 protein, human</str><str>trappc1 protein, human</str><str>multiple myeloma patients with no documentation of prescribed or received intravenous bisphosphonate therapy</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; smoldering, stage i (for use in a medicare-approved demonstration project)</str><str>myeov protein, human</str><str>Multiple Myeloma Bone Disease</str><str>Refractory Multiple Myeloma</str><str>Hematologic Malignancies, Multiple Myeloma, Lymphoma</str><str>Relapsed or Refractory Multiple Myeloma</str><str>Smoldering Multiple Myeloma</str><str>Relapsed Multiple Myeloma</str><str>Multiple Myeloma With Plasmacytoma</str><str>Relapsed and Refractory Multiple Myeloma</str><str>Hodgkin's Disease or Multiple Myeloma</str><str>Relapsed and/or Refractory Multiple Myeloma</str></arr><arr name="coordinates"><str>44.971965,-93.23588</str></arr><arr name="criteria"><str>Patients meeting the Durie and Salmon criteria for initial diagnosis of multiple</str><str>myeloma.</str><str>All patients with multiple myeloma requiring therapy.</str><str>Patients less than or equal to 70 years of age.</str><str>Patients will be eligible after initial therapy in either first complete or partial</str><str>remission or if no objective response is achieved.</str><str>Patients achieving initial response and later disease progression will be eligible</str><str>after subsequent therapy upon achievement of either complete or partial response.</str><str>Patients will be ineligible if they have advanced myeloma refractory to salvage</str><str>chemotherapy regimens.</str><str>To be eligible  patients must have adequate: cardiac function (no active ischemia</str><str>left ventricular ejection fraction &gt; 45% by MUGA scan); renal function (creatinine</str><str>clearance &gt; 40 ml/min); liver function (bilirubin &lt; 2.0 mg/dl  ALT &lt; 3x the upper</str><str>limit of normal); adequate pulmonary function (FEV1 AND FVC &gt;50% predicted and DLCO</str><str>(corrected) &gt; 50% predicted; and Karnofsky performance of &gt; 80%.</str><str>Patients must be free of active uncontrolled infection at the time of study entry.</str><str>Patients must have adequate hematologic function manifest as hemoglobin &gt; 8 gm/dl</str><str>(untransfused); WBC &gt; 3000/ml; absolute neutrophil count (ANC) &gt; 1500/ml; and</str><str>platelets &gt; 100 000/ml (untransfused).</str><str>At study entry patients must be &gt; 4 weeks from prior myelosuppressive chemotherapy;</str><str>and &gt; 6 weeks from prior nitrosoureas.</str><str>Female patients who are pregnant (positive b-HCG) or breastfeeding will be excluded</str><str>from study entry. In addition fertile men or women unwilling to use contraceptive</str><str>techniques during and for 4 weeks following completion of maintenance therapy  will</str><str>also be excluded from study entry.</str><str>Patients must exercise informed voluntary consent and sign a consent form approved by</str><str>the University of Minnesota IRB: Human Subjects Committee.</str><str>Patients will be ineligible if they have advanced myeloma refractory and unresponsive</str><str>to salvage chemotherapy regimens.</str><str>Female patients who are pregnant (positive b-HCG) or breastfeeding will be excluded</str><str>from study entry. In addition fertile men or women unwilling to use contraceptive</str><str>techniques during and for 12 months following treatment  particularly after</str><str>thalidomide will also be excluded from study entry.</str><str>Patients meeting the Durie and Salmon criteria for initial diagnosis of multiple</str><str>myeloma, requiring therapy and meeting one of the following:</str><str>After initial therapy in either first complete or partial remission or no</str><str>objective response</str><str>After achieving initial response and later disease progression, patient will be</str><str>eligible after subsequent therapy upon achievement of either complete or partial</str><str>response</str><str>Is not eligible or has refused any protocols of higher priority</str><str>18 - 75 years of age</str><str>Adequate organ function defined as:</str><str>Hematologic: hemoglobin ≥ 8 gm/dl (untransfused), white blood cells (WBC) ≥</str><str>3000/μl, absolute neutrophil count (ANC) ≥ 1500/μl, platelets ≥ 100,000/μl</str><str>(untransfused)</str><str>Cardiac: no active ischemia, left ventricular ejection fraction &gt; 45% by MUGA</str><str>can</str><str>Hepatic: bilirubin &lt; 2.0 mg/dl, ALT &lt; 3x the upper limit of normal</str><str>Pulmonary: FEV1-Forced Expiratory Volume in One Second AND Forced vital capacity</str><str>(FVC) &gt;50% predicted and Carbon Monoxide Diffusing Capacity (DLCO) (corrected) &gt;</str><str>50% predicted</str><str>Performance status: Karnofsky performance of &gt; 80%.</str><str>Free of active uncontrolled infection at the time of study entry.</str><str>At time of study enrollment &gt; 4 weeks from prior myelosuppressive chemotherapy; and &gt;</str><str>6 weeks from prior nitrosoureas.</str><str>Patients must exercise informed voluntary consent and sign a consent form approved by</str><str>the University of Minnesota IRB: Human Subjects Committee.</str><str>Patients will be ineligible if they have advanced myeloma refractory and unresponsive</str><str>to salvage chemotherapy regimens.</str><str>Female patients who are pregnant (positive b-HCG) or breastfeeding will be excluded</str><str>from study entry. In addition fertile men or women unwilling to use contraceptive</str><str>techniques during and for 12 months following treatment, particularly after</str><str>thalidomide will also be excluded from study entry.</str><str>Patients meeting the Durie and Salmon criteria for initial diagnosis of multiple</str><str>myeloma, requiring therapy and meeting one of the following:</str><str>After initial therapy in either first complete or partial remission or no</str><str>objective response</str><str>After achieving initial response and later disease progression, patient will be</str><str>eligible after subsequent therapy upon achievement of either complete or partial</str><str>response</str><str>Is not eligible or has refused any protocols of higher priority</str><str>18 - 75 years of age</str><str>Adequate organ function defined as:</str><str>Hematologic: hemoglobin ≥ 8 gm/dl (untransfused), white blood cells (WBC) ≥</str><str>3000/μl, absolute neutrophil count (ANC) ≥ 1500/μl, platelets ≥ 100,000/μl</str><str>(untransfused)</str><str>Cardiac: no active ischemia, left ventricular ejection fraction &gt; 45% by MUGA</str><str>can</str><str>Hepatic: bilirubin &lt; 2.0 mg/dl, ALT &lt; 3x the upper limit of normal</str><str>Pulmonary: FEV1-Forced Expiratory Volume in One Second AND Forced vital capacity</str><str>(FVC) &gt;50% predicted and Carbon Monoxide Diffusing Capacity (DLCO) (corrected) &gt;</str><str>50% predicted</str><str>Performance status: Karnofsky performance of &gt; 80%.</str><str>Free of active uncontrolled infection at the time of study entry.</str><str>At time of study enrollment &gt; 4 weeks from prior myelosuppressive chemotherapy; and &gt;</str><str>6 weeks from prior nitrosoureas.</str><str>Patients must exercise informed voluntary consent and sign a consent form approved by</str><str>the University of Minnesota IRB: Human Subjects Committee.</str><str>Patients will be ineligible if they have advanced myeloma refractory and unresponsive</str><str>to salvage chemotherapy regimens.</str><str>Female patients who are pregnant (positive b-HCG) or breastfeeding will be excluded</str><str>from study entry. In addition fertile men or women unwilling to use contraceptive</str><str>techniques during and for 12 months following treatment, particularly after</str><str>thalidomide will also be excluded from study entry.</str><str>Patients meeting the Durie and Salmon criteria for initial diagnosis of multiple</str><str>myeloma, requiring therapy and meeting one of the following:</str><str>After initial therapy in either first complete or partial remission or no</str><str>objective response</str><str>After achieving initial response and later disease progression, patient will be</str><str>eligible after subsequent therapy upon achievement of either complete or partial</str><str>response</str><str>Is not eligible or has refused any protocols of higher priority</str><str>18 - 75 years of age</str><str>Adequate organ function defined as:</str><str>Hematologic: hemoglobin ≥ 8 gm/dl (untransfused), white blood cells (WBC) ≥</str><str>3000/μl, absolute neutrophil count (ANC) ≥ 1500/μl, platelets ≥ 100,000/μl</str><str>(untransfused)</str><str>Cardiac: no active ischemia, left ventricular ejection fraction &gt; 45% by MUGA</str><str>can</str><str>Hepatic: bilirubin &lt; 2.0 mg/dl, ALT &lt; 3x the upper limit of normal</str><str>Pulmonary: FEV1-Forced Expiratory Volume in One Second AND Forced vital capacity</str><str>(FVC) &gt;50% predicted and Carbon Monoxide Diffusing Capacity (DLCO) (corrected) &gt;</str><str>50% predicted</str><str>Performance status: Karnofsky performance of &gt; 80%.</str><str>Free of active uncontrolled infection at the time of study entry.</str><str>At time of study enrollment &gt; 4 weeks from prior myelosuppressive chemotherapy; and &gt;</str><str>6 weeks from prior nitrosoureas.</str><str>Patients must exercise informed voluntary consent and sign a consent form approved by</str><str>the University of Minnesota IRB: Human Subjects Committee.</str><str>Patients will be ineligible if they have advanced myeloma refractory and unresponsive</str><str>to salvage chemotherapy regimens.</str><str>Female patients who are pregnant (positive b-HCG) or breastfeeding will be excluded</str><str>from study entry. In addition fertile men or women unwilling to use contraceptive</str><str>techniques during and for 12 months following treatment, particularly after</str><str>thalidomide will also be excluded from study entry.</str><str>Patients meeting the Durie and Salmon criteria for initial diagnosis of multiple</str><str>myeloma, requiring therapy and meeting one of the following:</str><str>After initial therapy in either first complete or partial remission or no</str><str>objective response</str><str>After achieving initial response and later disease progression, patient will be</str><str>eligible after subsequent therapy upon achievement of either complete or partial</str><str>response</str><str>Is not eligible or has refused any protocols of higher priority</str><str>18 - 75 years of age</str><str>Adequate organ function defined as:</str><str>Hematologic: hemoglobin ≥ 8 gm/dl (untransfused), white blood cells (WBC) ≥</str><str>3000/μl, absolute neutrophil count (ANC) ≥ 1500/μl, platelets ≥ 100,000/μl</str><str>(untransfused)</str><str>Cardiac: no active ischemia, left ventricular ejection fraction &gt; 45% by MUGA</str><str>can</str><str>Hepatic: bilirubin &lt; 2.0 mg/dl, ALT &lt; 3x the upper limit of normal</str><str>Pulmonary: FEV1-Forced Expiratory Volume in One Second AND Forced vital capacity</str><str>(FVC) &gt;50% predicted and Carbon Monoxide Diffusing Capacity (DLCO) (corrected) &gt;</str><str>50% predicted</str><str>Performance status: Karnofsky performance of &gt; 80%.</str><str>Free of active uncontrolled infection at the time of study entry.</str><str>At time of study enrollment &gt; 4 weeks from prior myelosuppressive chemotherapy; and &gt;</str><str>6 weeks from prior nitrosoureas.</str><str>Patients must exercise informed voluntary consent and sign a consent form approved by</str><str>the University of Minnesota IRB: Human Subjects Committee.</str><str>Patients will be ineligible if they have advanced myeloma refractory and unresponsive</str><str>to salvage chemotherapy regimens.</str><str>Female patients who are pregnant (positive b-HCG) or breastfeeding will be excluded</str><str>from study entry. In addition fertile men or women unwilling to use contraceptive</str><str>techniques during and for 12 months following treatment, particularly after</str><str>thalidomide will also be excluded from study entry.</str><str>Patients meeting the Durie and Salmon criteria for initial diagnosis of multiple</str><str>myeloma, requiring therapy and meeting one of the following:</str><str>After initial therapy in either first complete or partial remission or no</str><str>objective response</str><str>After achieving initial response and later disease progression, patient will be</str><str>eligible after subsequent therapy upon achievement of either complete or partial</str><str>response</str><str>Is not eligible or has refused any protocols of higher priority</str><str>18 - 75 years of age</str><str>Adequate organ function defined as:</str><str>Hematologic: hemoglobin ≥ 8 gm/dl (untransfused), white blood cells (WBC) ≥</str><str>3000/μl, absolute neutrophil count (ANC) ≥ 1500/μl, platelets ≥ 100,000/μl</str><str>(untransfused)</str><str>Cardiac: no active ischemia, left ventricular ejection fraction &gt; 45% by MUGA</str><str>can</str><str>Hepatic: bilirubin &lt; 2.0 mg/dl, ALT &lt; 3x the upper limit of normal</str><str>Pulmonary: FEV1-Forced Expiratory Volume in One Second AND Forced vital capacity</str><str>(FVC) &gt;50% predicted and Carbon Monoxide Diffusing Capacity (DLCO) (corrected) &gt;</str><str>50% predicted</str><str>Performance status: Karnofsky performance of &gt; 80%.</str><str>Free of active uncontrolled infection at the time of study entry.</str><str>At time of study enrollment &gt; 4 weeks from prior myelosuppressive chemotherapy; and &gt;</str><str>6 weeks from prior nitrosoureas.</str><str>Patients must exercise informed voluntary consent and sign a consent form approved by</str><str>the University of Minnesota IRB: Human Subjects Committee.</str><str>Patients will be ineligible if they have advanced myeloma refractory and unresponsive</str><str>to salvage chemotherapy regimens.</str><str>Female patients who are pregnant (positive b-HCG) or breastfeeding will be excluded</str><str>from study entry. In addition fertile men or women unwilling to use contraceptive</str><str>techniques during and for 12 months following treatment, particularly after</str><str>thalidomide will also be excluded from study entry.</str></arr><str name="display_conditions">Multiple Myeloma</str><str name="django_ct">txdb.trial</str><str name="django_id">69256</str><str name="gender">Both</str><bool name="has_investigator">true</bool><str name="id">txdb.trial.69256</str><bool name="is_featured">false</bool><bool name="isactive">true</bool><bool name="isusersubmitted">false</bool><date name="lchangetime">2011-01-11T00:00:00Z</date><long name="maxage">75</long><long name="minage">18</long><str name="nctIdentifier">NCT00177047</str><long name="phase">0</long><float name="rank">0.8</float><str name="show_transplant_trials">yes</str><arr name="sitenames"><str>Masonic Cancer Center, University of Minnesota</str></arr><arr name="state"><str>MN</str></arr><str name="study_type">Interventional</str><str name="title">Autologous Transplant for Multiple Myeloma</str><arr name="treatment_name"><str>Stem Cell Transplant</str><str>cyclophosphamide, melphalan</str><str>Thalidomide and Dexamethasone</str><str>Cyclophosphamide + Mesna</str><str>thalidomide</str><str>melphalan</str><str>Granulocyte-colony stimulating factor</str><str>dexamethasone</str></arr><arr name="treatment_status"><str>refractory</str><str>Refractory</str></arr><str name="weburl">multiple-myeloma-autologous-transplant-multiple-myeloma</str><arr name="zipcode"><str>55455</str></arr></doc><doc><arr name="city"><str>Little Rock</str></arr><arr name="conditions"><str>Multiple Myeloma</str><str>Multiple Myeloma and Plasma Cell Neoplasm</str><str>Multiple Myeloma And Immunoproliferative Neoplasms</str><str>Mult Myelm W/O Remission</str><str>Mult Myelm W Remission</str><str>Multiple Myeloma Stage I</str><str>Multiple Myeloma Stage Ii</str><str>Multiple Myeloma Stage Iii</str><str>Fgfr3/Igh Fusion</str><str>Increased Risk For Multiple Myeloma</str><str>Lig4, Ala3val</str><str>Lig4, Thr9ile</str><str>m protein, multiple myeloma</str><str>prevention of multiple myeloma</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; stage ii or higher (for use in a medicare-approved demonstration project)</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; extent of disease unknown, </str><str>whsc1 protein, human</str><str>trappc1 protein, human</str><str>multiple myeloma patients with no documentation of prescribed or received intravenous bisphosphonate therapy</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; smoldering, stage i (for use in a medicare-approved demonstration project)</str><str>myeov protein, human</str><str>Multiple Myeloma Bone Disease</str><str>Refractory Multiple Myeloma</str><str>Hematologic Malignancies, Multiple Myeloma, Lymphoma</str><str>Relapsed or Refractory Multiple Myeloma</str><str>Smoldering Multiple Myeloma</str><str>Relapsed Multiple Myeloma</str><str>Multiple Myeloma With Plasmacytoma</str><str>Relapsed and Refractory Multiple Myeloma</str><str>Hodgkin's Disease or Multiple Myeloma</str><str>Relapsed and/or Refractory Multiple Myeloma</str></arr><arr name="coordinates"><str>34.752391,-92.3355</str></arr><arr name="criteria"><str>Any subject evaluated for a MIRT protocol</str><str>Subjects who have not been evaluated for a MIRT protocol</str><str>Any subject evaluated for a MIRT protocol</str><str>Subjects who have not been evaluated for a MIRT protocol</str><str>Any subject evaluated for a MIRT protocol</str><str>Subjects who have not been evaluated for a MIRT protocol</str><str>Any subject evaluated for a MIRT protocol</str><str>Subjects who have not been evaluated for a MIRT protocol</str><str>Any subject evaluated for a MIRT protocol</str><str>Subjects who have not been evaluated for a MIRT protocol</str><str>Any subject evaluated for a MIRT protocol</str><str>Subjects who have not been evaluated for a MIRT protocol</str><str>Any subject evaluated for a MIRT protocol</str><str>Subjects who have not been evaluated for a MIRT protocol</str></arr><str name="display_conditions">Multiple Myeloma</str><str name="django_ct">txdb.trial</str><str name="django_id">76355</str><str name="gender">Both</str><bool name="has_investigator">true</bool><str name="id">txdb.trial.76355</str><bool name="is_featured">false</bool><bool name="isactive">true</bool><bool name="isusersubmitted">false</bool><date name="lchangetime">2011-01-18T00:00:00Z</date><long name="maxage">100</long><long name="minage">18</long><str name="nctIdentifier">NCT00572338</str><long name="phase">0</long><float name="rank">0.2</float><str name="show_transplant_trials">no</str><arr name="sitenames"><str>University of Arkansas for Medical Sciences/MIRT</str></arr><arr name="state"><str>AR</str></arr><str name="study_type">Observational</str><str name="title">Therapeutic Research in Multiple Myeloma</str><arr name="treatment_name"><str>No drugs are involved</str></arr><str name="weburl">multiple-myeloma-therapeutic-research-multiple-myeloma</str><arr name="zipcode"><str>72205</str></arr></doc><doc><arr name="city"><str>Salt Lake City</str></arr><arr name="conditions"><str>Multiple Myeloma</str><str>Multiple Myeloma and Plasma Cell Neoplasm</str><str>Multiple Myeloma And Immunoproliferative Neoplasms</str><str>Mult Myelm W/O Remission</str><str>Mult Myelm W Remission</str><str>Multiple Myeloma Stage I</str><str>Multiple Myeloma Stage Ii</str><str>Multiple Myeloma Stage Iii</str><str>Fgfr3/Igh Fusion</str><str>Increased Risk For Multiple Myeloma</str><str>Lig4, Ala3val</str><str>Lig4, Thr9ile</str><str>m protein, multiple myeloma</str><str>prevention of multiple myeloma</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; stage ii or higher (for use in a medicare-approved demonstration project)</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; extent of disease unknown, </str><str>whsc1 protein, human</str><str>trappc1 protein, human</str><str>multiple myeloma patients with no documentation of prescribed or received intravenous bisphosphonate therapy</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; smoldering, stage i (for use in a medicare-approved demonstration project)</str><str>myeov protein, human</str><str>Multiple Myeloma Bone Disease</str><str>Refractory Multiple Myeloma</str><str>Hematologic Malignancies, Multiple Myeloma, Lymphoma</str><str>Relapsed or Refractory Multiple Myeloma</str><str>Smoldering Multiple Myeloma</str><str>Relapsed Multiple Myeloma</str><str>Multiple Myeloma With Plasmacytoma</str><str>Relapsed and Refractory Multiple Myeloma</str><str>Hodgkin's Disease or Multiple Myeloma</str><str>Relapsed and/or Refractory Multiple Myeloma</str></arr><arr name="coordinates"><str>40.76784,-111.83805</str></arr><arr name="criteria"><str>Patients with relapsed/refractory multiple myeloma to at least one line of prior</str><str>therapy</str><str>Male or female patients aged ≥ 18 years old</str><str>Ability to provide written informed consent obtained prior to participation in the</str><str>tudy and any related procedures being performed</str><str>Patients are allowed to receive growth factors (erythropoietin hormones, GCSF and</str><str>GMCSF)</str><str>Patients must meet the following laboratory criteria:</str><str>ANC ≥ 1.5 x 109/L</str><str>Hemoglobin ≥ 9 g/dl</str><str>Platelets ≥ 100x 109/L</str><str>Calculated CrCl &gt; 50 mL/min (MDRD Formula)</str><str>AST and ALT ≤ 2.5 x ULN</str><str>Serum bilirubin &lt; 2.0 x ULN</str><str>Albumin &gt; 3.0 g/dl</str><str>Serum potassium ≥ LLN for the institution</str><str>Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN, for</str><str>the institution</str><str>Serum magnesium ≥ LLN for the institution</str><str>Serum phosphorus ≥ LLN for the institution</str><str>TSH ≤ LLN and free T4 within normal limits. Patients are permitted to receive</str><str>thyroid hormone supplements to treat underlying hypothyroidism.</str><str>Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional</str><str>normal.</str><str>History of histologically documented MM with relapsed or progressive disease after at</str><str>least one line of prior therapy.</str><str>Patient has measurable disease in which to capture response, defined as one or more of</str><str>the following:</str><str>Serum M-protein level ≥ 0.5 gm/dl (10.0 g/L) measured by serum protein</str><str>electrophoresis or immunoglobulin electrophoresis; or</str><str>Urinary M-protein excretion ≥ 200 mg/24 hrs; or</str><str>Bone marrow plasmacytosis of ≥ 30% by bone marrow aspirate and/or biopsy; or</str><str>Serum Free Light Chains (By the Freelite test) &gt; 2X ULN, in the absence of renal</str><str>failure</str><str>Performance status of ≤ 2 as per ECOG scale, unless PS of 3-4 based solely on bone</str><str>pain.</str><str>Patients must have signed an IRB approved written informed consent form and</str><str>demonstrate willingness to meet follow-up schedule and study procedure obligations</str><str>Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer</str><str>Patients who have received Velcade within 2 months of enrollment</str><str>Patients who will need valproic acid for any medical condition during the study or</str><str>within 5 days prior to first panobinostat IV treatment</str><str>Peripheral neuropathy &gt; grade 2.</str><str>Impaired cardiac function or clinically significant cardiac diseases, including any</str><str>one of the following:</str><str>Patients with congenital long QT syndrome</str><str>History or presence of sustained ventricular tachyarrhythmia. (Patients with a</str><str>history of atrial arrhythmia are eligible but should be discussed with Novartis</str><str>prior to enrollment)</str><str>Any history of ventricular fibrillation or torsade de pointes</str><str>Bradycardia defined as HR&lt; 50 bpm. Patients with pacemakers are eligible if HR ≥</str><str>50 bpm.</str><str>Screening ECG with a QTc &gt; 450 msec</str><str>Right bundle branch block + left anterior hemiblock (bifascicular block)</str><str>Patients with myocardial infarction or unstable angina  ≤ 6 months prior to</str><str>tarting study drug</str><str>Other clinically significant heart disease (e.g., CHF NY Heart Association class</str><str>III or IV , uncontrolled hypertension, history of labile hypertension, or history</str><str>of poor compliance with an antihypertensive regimen)</str><str>Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled</str><str>diabetes or active or uncontrolled infection) including abnormal laboratory values,</str><str>that could cause unacceptable safety risks or compromise compliance with the protocol</str><str>Patients using medications that have a relative risk of prolonging the QT interval or</str><str>inducing torsade de pointes if treatment cannot be discontinued or switched to a</str><str>different medication prior to starting study drug</str><str>Concomitant use of CYP3A4 inhibitors (See Appendix 2)</str><str>Patients who have received targeted agents within 2 weeks or within 5 half-lives of</str><str>the agent and active metabolites (which ever is longer) and who have not recovered</str><str>from side effects of those therapies.</str><str>Patients who have received either immunotherapy (e.g. vaccines) within &lt; 8 weeks;</str><str>chemotherapy within &lt; 4 weeks; or radiation therapy to &gt; 30% of marrow-bearing bone</str><str>within &lt; 2 weeks prior to starting study treatment; or who have not yet recovered from</str><str>ide effects of such therapies.</str><str>Patients with an active bleeding tendency or is receiving any treatment with</str><str>therapeutic doses of sodium warfarin (Coumadin®) or coumadin derivatives. Low doses of</str><str>Coumadin® (e.g. ≤ 2.0 mg/day) to maintain line patency (if applicable) is allowed.</str><str>Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or</str><str>who have not recovered from side effects of such therapy</str><str>Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)</str><str>not using an effective method of birth control. WOCBP are defined as sexually mature</str><str>women who have not undergone a hysterectomy or who have not been naturally</str><str>postmenopausal for at least 12 consecutive months (i.e., who has had menses any time</str><str>in the preceding 12 consecutive months). Women of childbearing potential must have a</str><str>negative serum pregnancy test within 24hrs of receiving the first dose of study</str><str>medication.</str><str>Male patients whose sexual partners are WOCBP not using effective birth control</str><str>Patients with a prior malignancy with in the last 5 years (except for basal  or</str><str>quamous cell carcinoma, or in situ cancer of the cervix)</str><str>Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis</str><str>C; baseline testing for HIV and hepatitis C is not required</str><str>Patients with any significant history of non-compliance to medical regimens or</str><str>unwilling or unable to comply with the instructions given to him/her by the study</str><str>taff.</str><str>No concomitant use of bisphosponates is allowed</str><str>Patients with relapsed/refractory multiple myeloma to at least one line of prior</str><str>therapy</str><str>Male or female patients aged ≥ 18 years old</str><str>Ability to provide written informed consent obtained prior to participation in the</str><str>tudy and any related procedures being performed</str><str>Patients are allowed to receive growth factors (erythropoietin hormones, GCSF and</str><str>GMCSF)</str><str>Patients must meet the following laboratory criteria:</str><str>ANC ≥ 1.5 x 109/L</str><str>Hemoglobin ≥ 9 g/dl</str><str>Platelets ≥ 100x 109/L</str><str>Calculated CrCl &gt; 50 mL/min (MDRD Formula)</str><str>AST and ALT ≤ 2.5 x ULN</str><str>Serum bilirubin &lt; 2.0 x ULN</str><str>Albumin &gt; 3.0 g/dl</str><str>Serum potassium ≥ LLN for the institution</str><str>Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN, for</str><str>the institution</str><str>Serum magnesium ≥ LLN for the institution</str><str>Serum phosphorus ≥ LLN for the institution</str><str>TSH ≤ LLN and free T4 within normal limits. Patients are permitted to receive</str><str>thyroid hormone supplements to treat underlying hypothyroidism.</str><str>Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional</str><str>normal.</str><str>History of histologically documented MM with relapsed or progressive disease after at</str><str>least one line of prior therapy.</str><str>Patient has measurable disease in which to capture response, defined as one or more</str><str>of the following:</str><str>Serum M-protein level ≥ 0.5 gm/dl (10.0 g/L) measured by serum protein</str><str>electrophoresis or immunoglobulin electrophoresis; or</str><str>Urinary M-protein excretion ≥ 200 mg/24 hrs; or</str><str>Bone marrow plasmacytosis of ≥ 30% by bone marrow aspirate and/or biopsy; or</str><str>Serum Free Light Chains (By the Freelite test) &gt; 2X ULN, in the absence of renal</str><str>failure</str><str>Performance status of ≤ 2 as per ECOG scale, unless PS of 3-4 based solely on bone</str><str>pain.</str><str>Patients must have signed an IRB approved written informed consent form and</str><str>demonstrate willingness to meet follow-up schedule and study procedure obligations</str><str>Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer</str><str>Patients who have received Velcade within 2 months of enrollment</str><str>Patients who will need valproic acid for any medical condition during the study or</str><str>within 5 days prior to first panobinostat IV treatment</str><str>Peripheral neuropathy &gt; grade 2.</str><str>Impaired cardiac function or clinically significant cardiac diseases, including any</str><str>one of the following:</str><str>Patients with congenital long QT syndrome</str><str>History or presence of sustained ventricular tachyarrhythmia. (Patients with a</str><str>history of atrial arrhythmia are eligible but should be discussed with Novartis</str><str>prior to enrollment)</str><str>Any history of ventricular fibrillation or torsade de pointes</str><str>Bradycardia defined as HR&lt; 50 bpm. Patients with pacemakers are eligible if HR ≥</str><str>50 bpm.</str><str>Screening ECG with a QTc &gt; 450 msec</str><str>Right bundle branch block + left anterior hemiblock (bifascicular block)</str><str>Patients with myocardial infarction or unstable angina  ≤ 6 months prior to</str><str>tarting study drug</str><str>Other clinically significant heart disease (e.g., CHF NY Heart Association class</str><str>III or IV , uncontrolled hypertension, history of labile hypertension, or</str><str>history of poor compliance with an antihypertensive regimen)</str><str>Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled</str><str>diabetes or active or uncontrolled infection) including abnormal laboratory values,</str><str>that could cause unacceptable safety risks or compromise compliance with the protocol</str><str>Patients using medications that have a relative risk of prolonging the QT interval or</str><str>inducing torsade de pointes if treatment cannot be discontinued or switched to a</str><str>different medication prior to starting study drug</str><str>Concomitant use of CYP3A4 inhibitors (See Appendix 2)</str><str>Patients who have received targeted agents within 2 weeks or within 5 half-lives of</str><str>the agent and active metabolites (which ever is longer) and who have not recovered</str><str>from side effects of those therapies.</str><str>Patients who have received either immunotherapy (e.g. vaccines) within &lt; 8 weeks;</str><str>chemotherapy within &lt; 4 weeks; or radiation therapy to &gt; 30% of marrow-bearing bone</str><str>within &lt; 2 weeks prior to starting study treatment; or who have not yet recovered</str><str>from side effects of such therapies.</str><str>Patients with an active bleeding tendency or is receiving any treatment with</str><str>therapeutic doses of sodium warfarin (Coumadin®) or coumadin derivatives. Low doses</str><str>of Coumadin® (e.g. ≤ 2.0 mg/day) to maintain line patency (if applicable) is allowed.</str><str>Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or</str><str>who have not recovered from side effects of such therapy</str><str>Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)</str><str>not using an effective method of birth control. WOCBP are defined as sexually mature</str><str>women who have not undergone a hysterectomy or who have not been naturally</str><str>postmenopausal for at least 12 consecutive months (i.e., who has had menses any time</str><str>in the preceding 12 consecutive months). Women of childbearing potential must have a</str><str>negative serum pregnancy test within 24hrs of receiving the first dose of study</str><str>medication.</str><str>Male patients whose sexual partners are WOCBP not using effective birth control</str><str>Patients with a prior malignancy with in the last 5 years (except for basal  or</str><str>quamous cell carcinoma, or in situ cancer of the cervix)</str><str>Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis</str><str>C; baseline testing for HIV and hepatitis C is not required</str><str>Patients with any significant history of non-compliance to medical regimens or</str><str>unwilling or unable to comply with the instructions given to him/her by the study</str><str>taff.</str><str>No concomitant use of bisphosponates is allowed</str><str>Patients with relapsed/refractory multiple myeloma to at least one line of prior</str><str>therapy</str><str>Male or female patients aged ≥ 18 years old</str><str>Ability to provide written informed consent obtained prior to participation in the</str><str>tudy and any related procedures being performed</str><str>Patients are allowed to receive growth factors (erythropoietin hormones, GCSF and</str><str>GMCSF)</str><str>Patients must meet the following laboratory criteria:</str><str>ANC ≥ 1.5 x 109/L</str><str>Hemoglobin ≥ 9 g/dl</str><str>Platelets ≥ 100x 109/L</str><str>Calculated CrCl &gt; 50 mL/min (MDRD Formula)</str><str>AST and ALT ≤ 2.5 x ULN</str><str>Serum bilirubin &lt; 2.0 x ULN</str><str>Albumin &gt; 3.0 g/dl</str><str>Serum potassium ≥ LLN for the institution</str><str>Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN, for</str><str>the institution</str><str>Serum magnesium ≥ LLN for the institution</str><str>Serum phosphorus ≥ LLN for the institution</str><str>TSH ≤ LLN and free T4 within normal limits. Patients are permitted to receive</str><str>thyroid hormone supplements to treat underlying hypothyroidism</str><str>Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional</str><str>normal</str><str>History of histologically documented MM with relapsed or progressive disease after at</str><str>least one line of prior therapy</str><str>Patient has measurable disease in which to capture response, defined as one or more</str><str>of the following:</str><str>Serum M-protein level ≥ 0.5 gm/dl (10.0 g/L) measured by serum protein</str><str>electrophoresis or immunoglobulin electrophoresis; or</str><str>Urinary M-protein excretion ≥ 200 mg/24 hrs; or</str><str>Bone marrow plasmacytosis of ≥ 30% by bone marrow aspirate and/or biopsy; or</str><str>Serum Free Light Chains (By the Freelite test) &gt; 2X ULN, in the absence of renal</str><str>failure</str><str>Performance status of ≤ 2 as per ECOG scale, unless PS of 3-4 based solely on bone</str><str>pain</str><str>Patients must have signed an IRB approved written informed consent form and</str><str>demonstrate willingness to meet follow-up schedule and study procedure obligations</str><str>Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer</str><str>Patients who have received Velcade within 2 months of enrollment</str><str>Patients who will need valproic acid for any medical condition during the study or</str><str>within 5 days prior to first panobinostat IV treatment</str><str>Peripheral neuropathy &gt; grade 2.</str><str>Impaired cardiac function or clinically significant cardiac diseases, including any</str><str>one of the following:</str><str>Patients with congenital long QT syndrome</str><str>History or presence of sustained ventricular tachyarrhythmia. (Patients with a</str><str>history of atrial arrhythmia are eligible but should be discussed with Novartis</str><str>prior to enrollment)</str><str>Any history of ventricular fibrillation or torsade de pointes</str><str>Bradycardia defined as HR&lt; 50 bpm. Patients with pacemakers are eligible if HR ≥</str><str>50 bpm.</str><str>Screening ECG with a QTc &gt; 450 msec</str><str>Right bundle branch block + left anterior hemiblock (bifascicular block)</str><str>Patients with myocardial infarction or unstable angina  ≤ 6 months prior to</str><str>tarting study drug</str><str>Other clinically significant heart disease (e.g., CHF NY Heart Association class</str><str>III or IV , uncontrolled hypertension, history of labile hypertension, or</str><str>history of poor compliance with an antihypertensive regimen)</str><str>Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled</str><str>diabetes or active or uncontrolled infection) including abnormal laboratory values,</str><str>that could cause unacceptable safety risks or compromise compliance with the protocol</str><str>Patients using medications that have a relative risk of prolonging the QT interval or</str><str>inducing torsade de pointes if treatment cannot be discontinued or switched to a</str><str>different medication prior to starting study drug</str><str>Concomitant use of CYP3A4 inhibitors (See Appendix 2)</str><str>Patients who have received targeted agents within 2 weeks or within 5 half-lives of</str><str>the agent and active metabolites (which ever is longer) and who have not recovered</str><str>from side effects of those therapies.</str><str>Patients who have received either immunotherapy (e.g. vaccines) within &lt; 8 weeks;</str><str>chemotherapy within &lt; 4 weeks; or radiation therapy to &gt; 30% of marrow-bearing bone</str><str>within &lt; 2 weeks prior to starting study treatment; or who have not yet recovered</str><str>from side effects of such therapies.</str><str>Patients with an active bleeding tendency or is receiving any treatment with</str><str>therapeutic doses of sodium warfarin (Coumadin®) or coumadin derivatives. Low doses</str><str>of Coumadin® (e.g. ≤ 2.0 mg/day) to maintain line patency (if applicable) is allowed.</str><str>Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or</str><str>who have not recovered from side effects of such therapy</str><str>Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)</str><str>not using an effective method of birth control. WOCBP are defined as sexually mature</str><str>women who have not undergone a hysterectomy or who have not been naturally</str><str>postmenopausal for at least 12 consecutive months (i.e., who has had menses any time</str><str>in the preceding 12 consecutive months). Women of childbearing potential must have a</str><str>negative serum pregnancy test within 24hrs of receiving the first dose of study</str><str>medication.</str><str>Male patients whose sexual partners are WOCBP not using effective birth control</str><str>Patients with a prior malignancy with in the last 5 years (except for basal  or</str><str>quamous cell carcinoma, or in situ cancer of the cervix)</str><str>Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis</str><str>C; baseline testing for HIV and hepatitis C is not required</str><str>Patients with any significant history of non-compliance to medical regimens or</str><str>unwilling or unable to comply with the instructions given to him/her by the study</str><str>taff.</str><str>No concomitant use of bisphosphonates is allowed</str><str>Patients with relapsed/refractory multiple myeloma to at least one line of prior</str><str>therapy</str><str>Male or female patients aged ≥ 18 years old</str><str>Ability to provide written informed consent obtained prior to participation in the</str><str>tudy and any related procedures being performed</str><str>Patients are allowed to receive growth factors (erythropoietin hormones, GCSF and</str><str>GMCSF)</str><str>Patients must meet the following laboratory criteria:</str><str>ANC ≥ 1.5 x 109/L</str><str>Hemoglobin ≥ 9 g/dl</str><str>Platelets ≥ 100x 109/L</str><str>Calculated CrCl &gt; 50 mL/min (MDRD Formula)</str><str>AST and ALT ≤ 2.5 x ULN</str><str>Serum bilirubin &lt; 2.0 x ULN</str><str>Albumin &gt; 3.0 g/dl</str><str>Serum potassium ≥ LLN for the institution</str><str>Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN, for</str><str>the institution</str><str>Serum magnesium ≥ LLN for the institution</str><str>Serum phosphorus ≥ LLN for the institution</str><str>TSH ≤ LLN and free T4 within normal limits. Patients are permitted to receive</str><str>thyroid hormone supplements to treat underlying hypothyroidism</str><str>Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional</str><str>normal</str><str>History of histologically documented MM with relapsed or progressive disease after at</str><str>least one line of prior therapy</str><str>Patient has measurable disease in which to capture response, defined as one or more</str><str>of the following:</str><str>Serum M-protein level ≥ 0.5 gm/dl (10.0 g/L) measured by serum protein</str><str>electrophoresis or immunoglobulin electrophoresis; or</str><str>Urinary M-protein excretion ≥ 200 mg/24 hrs; or</str><str>Bone marrow plasmacytosis of ≥ 30% by bone marrow aspirate and/or biopsy; or</str><str>Serum Free Light Chains (By the Freelite test) &gt; 2X ULN, in the absence of renal</str><str>failure</str><str>Performance status of ≤ 2 as per ECOG scale, unless PS of 3-4 based solely on bone</str><str>pain</str><str>Patients must have signed an IRB approved written informed consent form and</str><str>demonstrate willingness to meet follow-up schedule and study procedure obligations</str><str>Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer</str><str>Patients who have received Velcade within 2 months of enrollment</str><str>Patients who will need valproic acid for any medical condition during the study or</str><str>within 5 days prior to first panobinostat IV treatment</str><str>Peripheral neuropathy &gt; grade 2.</str><str>Impaired cardiac function or clinically significant cardiac diseases, including any</str><str>one of the following:</str><str>Patients with congenital long QT syndrome</str><str>History or presence of sustained ventricular tachyarrhythmia. (Patients with a</str><str>history of atrial arrhythmia are eligible but should be discussed with Novartis</str><str>prior to enrollment)</str><str>Any history of ventricular fibrillation or torsade de pointes</str><str>Bradycardia defined as HR&lt; 50 bpm. Patients with pacemakers are eligible if HR ≥</str><str>50 bpm.</str><str>Screening ECG with a QTc &gt; 450 msec</str><str>Right bundle branch block + left anterior hemiblock (bifascicular block)</str><str>Patients with myocardial infarction or unstable angina  ≤ 6 months prior to</str><str>tarting study drug</str><str>Other clinically significant heart disease (e.g., CHF NY Heart Association class</str><str>III or IV , uncontrolled hypertension, history of labile hypertension, or</str><str>history of poor compliance with an antihypertensive regimen)</str><str>Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled</str><str>diabetes or active or uncontrolled infection) including abnormal laboratory values,</str><str>that could cause unacceptable safety risks or compromise compliance with the protocol</str><str>Patients using medications that have a relative risk of prolonging the QT interval or</str><str>inducing torsade de pointes if treatment cannot be discontinued or switched to a</str><str>different medication prior to starting study drug</str><str>Concomitant use of CYP3A4 inhibitors (See Appendix 2)</str><str>Patients who have received targeted agents within 2 weeks or within 5 half-lives of</str><str>the agent and active metabolites (which ever is longer) and who have not recovered</str><str>from side effects of those therapies.</str><str>Patients who have received either immunotherapy (e.g. vaccines) within &lt; 8 weeks;</str><str>chemotherapy within &lt; 4 weeks; or radiation therapy to &gt; 30% of marrow-bearing bone</str><str>within &lt; 2 weeks prior to starting study treatment; or who have not yet recovered</str><str>from side effects of such therapies.</str><str>Patients with an active bleeding tendency or is receiving any treatment with</str><str>therapeutic doses of sodium warfarin (Coumadin®) or coumadin derivatives. Low doses</str><str>of Coumadin® (e.g. ≤ 2.0 mg/day) to maintain line patency (if applicable) is allowed.</str><str>Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or</str><str>who have not recovered from side effects of such therapy</str><str>Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)</str><str>not using an effective method of birth control. WOCBP are defined as sexually mature</str><str>women who have not undergone a hysterectomy or who have not been naturally</str><str>postmenopausal for at least 12 consecutive months (i.e., who has had menses any time</str><str>in the preceding 12 consecutive months). Women of childbearing potential must have a</str><str>negative serum pregnancy test within 24hrs of receiving the first dose of study</str><str>medication.</str><str>Male patients whose sexual partners are WOCBP not using effective birth control</str><str>Patients with a prior malignancy with in the last 5 years (except for basal  or</str><str>quamous cell carcinoma, or in situ cancer of the cervix)</str><str>Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis</str><str>C; baseline testing for HIV and hepatitis C is not required</str><str>Patients with any significant history of non-compliance to medical regimens or</str><str>unwilling or unable to comply with the instructions given to him/her by the study</str><str>taff.</str><str>No concomitant use of bisphosphonates is allowed</str><str>Patients with relapsed/refractory multiple myeloma to at least one line of prior</str><str>therapy</str><str>Male or female patients aged ≥ 18 years old</str><str>Ability to provide written informed consent obtained prior to participation in the</str><str>tudy and any related procedures being performed</str><str>Patients are allowed to receive growth factors (erythropoietin hormones, GCSF and</str><str>GMCSF)</str><str>Patients must meet the following laboratory criteria:</str><str>ANC ≥ 1.5 x 109/L</str><str>Hemoglobin ≥ 9 g/dl</str><str>Platelets ≥ 100x 109/L</str><str>Calculated CrCl &gt; 50 mL/min (MDRD Formula)</str><str>AST and ALT ≤ 2.5 x ULN</str><str>Serum bilirubin &lt; 2.0 x ULN</str><str>Albumin &gt; 3.0 g/dl</str><str>Serum potassium ≥ LLN for the institution</str><str>Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN, for</str><str>the institution</str><str>Serum magnesium ≥ LLN for the institution</str><str>Serum phosphorus ≥ LLN for the institution</str><str>TSH ≤ LLN and free T4 within normal limits. Patients are permitted to receive</str><str>thyroid hormone supplements to treat underlying hypothyroidism</str><str>Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional</str><str>normal</str><str>History of histologically documented MM with relapsed or progressive disease after at</str><str>least one line of prior therapy</str><str>Patient has measurable disease in which to capture response, defined as one or more</str><str>of the following:</str><str>Serum M-protein level ≥ 0.5 gm/dl (10.0 g/L) measured by serum protein</str><str>electrophoresis or immunoglobulin electrophoresis; or</str><str>Urinary M-protein excretion ≥ 200 mg/24 hrs; or</str><str>Bone marrow plasmacytosis of ≥ 30% by bone marrow aspirate and/or biopsy; or</str><str>Serum Free Light Chains (By the Freelite test) &gt; 2X ULN, in the absence of renal</str><str>failure</str><str>Performance status of ≤ 2 as per ECOG scale, unless PS of 3-4 based solely on bone</str><str>pain</str><str>Patients must have signed an IRB approved written informed consent form and</str><str>demonstrate willingness to meet follow-up schedule and study procedure obligations</str><str>Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer</str><str>Patients who have received Velcade within 2 months of enrollment</str><str>Patients who will need valproic acid for any medical condition during the study or</str><str>within 5 days prior to first panobinostat IV treatment</str><str>Peripheral neuropathy &gt; grade 2.</str><str>Impaired cardiac function or clinically significant cardiac diseases, including any</str><str>one of the following:</str><str>Patients with congenital long QT syndrome</str><str>History or presence of sustained ventricular tachyarrhythmia. (Patients with a</str><str>history of atrial arrhythmia are eligible but should be discussed with Novartis</str><str>prior to enrollment)</str><str>Any history of ventricular fibrillation or torsade de pointes</str><str>Bradycardia defined as HR&lt; 50 bpm. Patients with pacemakers are eligible if HR ≥</str><str>50 bpm.</str><str>Screening ECG with a QTc &gt; 450 msec</str><str>Right bundle branch block + left anterior hemiblock (bifascicular block)</str><str>Patients with myocardial infarction or unstable angina  ≤ 6 months prior to</str><str>tarting study drug</str><str>Other clinically significant heart disease (e.g., CHF NY Heart Association class</str><str>III or IV , uncontrolled hypertension, history of labile hypertension, or</str><str>history of poor compliance with an antihypertensive regimen)</str><str>Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled</str><str>diabetes or active or uncontrolled infection) including abnormal laboratory values,</str><str>that could cause unacceptable safety risks or compromise compliance with the protocol</str><str>Patients using medications that have a relative risk of prolonging the QT interval or</str><str>inducing torsade de pointes if treatment cannot be discontinued or switched to a</str><str>different medication prior to starting study drug</str><str>Concomitant use of CYP3A4 inhibitors (See Appendix 2)</str><str>Patients who have received targeted agents within 2 weeks or within 5 half-lives of</str><str>the agent and active metabolites (which ever is longer) and who have not recovered</str><str>from side effects of those therapies.</str><str>Patients who have received either immunotherapy (e.g. vaccines) within &lt; 8 weeks;</str><str>chemotherapy within &lt; 4 weeks; or radiation therapy to &gt; 30% of marrow-bearing bone</str><str>within &lt; 2 weeks prior to starting study treatment; or who have not yet recovered</str><str>from side effects of such therapies.</str><str>Patients with an active bleeding tendency or is receiving any treatment with</str><str>therapeutic doses of sodium warfarin (Coumadin®) or coumadin derivatives. Low doses</str><str>of Coumadin® (e.g. ≤ 2.0 mg/day) to maintain line patency (if applicable) is allowed.</str><str>Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or</str><str>who have not recovered from side effects of such therapy</str><str>Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)</str><str>not using an effective method of birth control. WOCBP are defined as sexually mature</str><str>women who have not undergone a hysterectomy or who have not been naturally</str><str>postmenopausal for at least 12 consecutive months (i.e., who has had menses any time</str><str>in the preceding 12 consecutive months). Women of childbearing potential must have a</str><str>negative serum pregnancy test within 24hrs of receiving the first dose of study</str><str>medication.</str><str>Male patients whose sexual partners are WOCBP not using effective birth control</str><str>Patients with a prior malignancy with in the last 5 years (except for basal  or</str><str>quamous cell carcinoma, or in situ cancer of the cervix)</str><str>Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis</str><str>C; baseline testing for HIV and hepatitis C is not required</str><str>Patients with any significant history of non-compliance to medical regimens or</str><str>unwilling or unable to comply with the instructions given to him/her by the study</str><str>taff.</str><str>No concomitant use of bisphosphonates is allowed</str><str>Patients with relapsed/refractory multiple myeloma to at least one line of prior</str><str>therapy</str><str>Male or female patients aged ≥ 18 years old</str><str>Ability to provide written informed consent obtained prior to participation in the</str><str>tudy and any related procedures being performed</str><str>Patients are allowed to receive growth factors (erythropoietin hormones, GCSF and</str><str>GMCSF)</str><str>Patients must meet the following laboratory criteria:</str><str>ANC ≥ 1.5 x 109/L</str><str>Hemoglobin ≥ 9 g/dl</str><str>Platelets ≥ 100x 109/L</str><str>Calculated CrCl &gt; 50 mL/min (MDRD Formula)</str><str>AST and ALT ≤ 2.5 x ULN</str><str>Serum bilirubin &lt; 2.0 x ULN</str><str>Albumin &gt; 3.0 g/dl</str><str>Serum potassium ≥ LLN for the institution</str><str>Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN, for</str><str>the institution</str><str>Serum magnesium ≥ LLN for the institution</str><str>Serum phosphorus ≥ LLN for the institution</str><str>TSH ≤ LLN and free T4 within normal limits. Patients are permitted to receive</str><str>thyroid hormone supplements to treat underlying hypothyroidism</str><str>Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional</str><str>normal</str><str>History of histologically documented MM with relapsed or progressive disease after at</str><str>least one line of prior therapy</str><str>Patient has measurable disease in which to capture response, defined as one or more</str><str>of the following:</str><str>Serum M-protein level ≥ 0.5 gm/dl (10.0 g/L) measured by serum protein</str><str>electrophoresis or immunoglobulin electrophoresis; or</str><str>Urinary M-protein excretion ≥ 200 mg/24 hrs; or</str><str>Bone marrow plasmacytosis of ≥ 30% by bone marrow aspirate and/or biopsy; or</str><str>Serum Free Light Chains (By the Freelite test) &gt; 2X ULN, in the absence of renal</str><str>failure</str><str>Performance status of ≤ 2 as per ECOG scale, unless PS of 3-4 based solely on bone</str><str>pain</str><str>Patients must have signed an IRB approved written informed consent form and</str><str>demonstrate willingness to meet follow-up schedule and study procedure obligations</str><str>Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer</str><str>Patients who have received Velcade within 2 months of enrollment</str><str>Patients who will need valproic acid for any medical condition during the study or</str><str>within 5 days prior to first panobinostat IV treatment</str><str>Peripheral neuropathy &gt; grade 2.</str><str>Impaired cardiac function or clinically significant cardiac diseases, including any</str><str>one of the following:</str><str>Patients with congenital long QT syndrome</str><str>History or presence of sustained ventricular tachyarrhythmia. (Patients with a</str><str>history of atrial arrhythmia are eligible but should be discussed with Novartis</str><str>prior to enrollment)</str><str>Any history of ventricular fibrillation or torsade de pointes</str><str>Bradycardia defined as HR&lt; 50 bpm. Patients with pacemakers are eligible if HR ≥</str><str>50 bpm.</str><str>Screening ECG with a QTc &gt; 450 msec</str><str>Right bundle branch block + left anterior hemiblock (bifascicular block)</str><str>Patients with myocardial infarction or unstable angina  ≤ 6 months prior to</str><str>tarting study drug</str><str>Other clinically significant heart disease (e.g., CHF NY Heart Association class</str><str>III or IV , uncontrolled hypertension, history of labile hypertension, or</str><str>history of poor compliance with an antihypertensive regimen)</str><str>Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled</str><str>diabetes or active or uncontrolled infection) including abnormal laboratory values,</str><str>that could cause unacceptable safety risks or compromise compliance with the protocol</str><str>Patients using medications that have a relative risk of prolonging the QT interval or</str><str>inducing torsade de pointes if treatment cannot be discontinued or switched to a</str><str>different medication prior to starting study drug</str><str>Concomitant use of CYP3A4 inhibitors (See Appendix 2)</str><str>Patients who have received targeted agents within 2 weeks or within 5 half-lives of</str><str>the agent and active metabolites (which ever is longer) and who have not recovered</str><str>from side effects of those therapies.</str><str>Patients who have received either immunotherapy (e.g. vaccines) within &lt; 8 weeks;</str><str>chemotherapy within &lt; 4 weeks; or radiation therapy to &gt; 30% of marrow-bearing bone</str><str>within &lt; 2 weeks prior to starting study treatment; or who have not yet recovered</str><str>from side effects of such therapies.</str><str>Patients with an active bleeding tendency or is receiving any treatment with</str><str>therapeutic doses of sodium warfarin (Coumadin®) or coumadin derivatives. Low doses</str><str>of Coumadin® (e.g. ≤ 2.0 mg/day) to maintain line patency (if applicable) is allowed.</str><str>Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or</str><str>who have not recovered from side effects of such therapy</str><str>Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)</str><str>not using an effective method of birth control. WOCBP are defined as sexually mature</str><str>women who have not undergone a hysterectomy or who have not been naturally</str><str>postmenopausal for at least 12 consecutive months (i.e., who has had menses any time</str><str>in the preceding 12 consecutive months). Women of childbearing potential must have a</str><str>negative serum pregnancy test within 24hrs of receiving the first dose of study</str><str>medication.</str><str>Male patients whose sexual partners are WOCBP not using effective birth control</str><str>Patients with a prior malignancy with in the last 5 years (except for basal  or</str><str>quamous cell carcinoma, or in situ cancer of the cervix)</str><str>Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis</str><str>C; baseline testing for HIV and hepatitis C is not required</str><str>Patients with any significant history of non-compliance to medical regimens or</str><str>unwilling or unable to comply with the instructions given to him/her by the study</str><str>taff.</str><str>No concomitant use of bisphosphonates is allowed</str><str>Patients with relapsed/refractory multiple myeloma to at least one line of prior</str><str>therapy</str><str>Male or female patients aged ≥ 18 years old</str><str>Ability to provide written informed consent obtained prior to participation in the</str><str>tudy and any related procedures being performed</str><str>Patients are allowed to receive growth factors (erythropoietin hormones, GCSF and</str><str>GMCSF)</str><str>Patients must meet the following laboratory criteria:</str><str>ANC ≥ 1.5 x 109/L</str><str>Hemoglobin ≥ 9 g/dl</str><str>Platelets ≥ 100x 109/L</str><str>Calculated CrCl &gt; 50 mL/min (MDRD Formula)</str><str>AST and ALT ≤ 2.5 x ULN</str><str>Serum bilirubin &lt; 2.0 x ULN</str><str>Albumin &gt; 3.0 g/dl</str><str>Serum potassium ≥ LLN for the institution</str><str>Total serum calcium [corrected for serum albumin] or ionized calcium ≥LLN, for</str><str>the institution</str><str>Serum magnesium ≥ LLN for the institution</str><str>Serum phosphorus ≥ LLN for the institution</str><str>TSH ≤ LLN and free T4 within normal limits. Patients are permitted to receive</str><str>thyroid hormone supplements to treat underlying hypothyroidism</str><str>Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional</str><str>normal</str><str>History of histologically documented MM with relapsed or progressive disease after at</str><str>least one line of prior therapy</str><str>Patient has measurable disease in which to capture response, defined as one or more</str><str>of the following:</str><str>Serum M-protein level ≥ 0.5 gm/dl (10.0 g/L) measured by serum protein</str><str>electrophoresis or immunoglobulin electrophoresis; or</str><str>Urinary M-protein excretion ≥ 200 mg/24 hrs; or</str><str>Bone marrow plasmacytosis of ≥ 30% by bone marrow aspirate and/or biopsy; or</str><str>Serum Free Light Chains (By the Freelite test) &gt; 2X ULN, in the absence of renal</str><str>failure</str><str>Performance status of ≤ 2 as per ECOG scale, unless PS of 3-4 based solely on bone</str><str>pain</str><str>Patients must have signed an IRB approved written informed consent form and</str><str>demonstrate willingness to meet follow-up schedule and study procedure obligations</str><str>Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer</str><str>Patients who have received Velcade within 2 months of enrollment</str><str>Patients who will need valproic acid for any medical condition during the study or</str><str>within 5 days prior to first panobinostat IV treatment</str><str>Peripheral neuropathy &gt; grade 2.</str><str>Impaired cardiac function or clinically significant cardiac diseases, including any</str><str>one of the following:</str><str>Patients with congenital long QT syndrome</str><str>History or presence of sustained ventricular tachyarrhythmia. (Patients with a</str><str>history of atrial arrhythmia are eligible but should be discussed with Novartis</str><str>prior to enrollment)</str><str>Any history of ventricular fibrillation or torsade de pointes</str><str>Bradycardia defined as HR&lt; 50 bpm. Patients with pacemakers are eligible if HR ≥</str><str>50 bpm.</str><str>Screening ECG with a QTc &gt; 450 msec</str><str>Right bundle branch block + left anterior hemiblock (bifascicular block)</str><str>Patients with myocardial infarction or unstable angina  ≤ 6 months prior to</str><str>tarting study drug</str><str>Other clinically significant heart disease (e.g., CHF NY Heart Association class</str><str>III or IV , uncontrolled hypertension, history of labile hypertension, or</str><str>history of poor compliance with an antihypertensive regimen)</str><str>Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled</str><str>diabetes or active or uncontrolled infection) including abnormal laboratory values,</str><str>that could cause unacceptable safety risks or compromise compliance with the protocol</str><str>Patients using medications that have a relative risk of prolonging the QT interval or</str><str>inducing torsade de pointes if treatment cannot be discontinued or switched to a</str><str>different medication prior to starting study drug</str><str>Concomitant use of CYP3A4 inhibitors (See Appendix 2)</str><str>Patients who have received targeted agents within 2 weeks or within 5 half-lives of</str><str>the agent and active metabolites (which ever is longer) and who have not recovered</str><str>from side effects of those therapies.</str><str>Patients who have received either immunotherapy (e.g. vaccines) within &lt; 8 weeks;</str><str>chemotherapy within &lt; 4 weeks; or radiation therapy to &gt; 30% of marrow-bearing bone</str><str>within &lt; 2 weeks prior to starting study treatment; or who have not yet recovered</str><str>from side effects of such therapies.</str><str>Patients with an active bleeding tendency or is receiving any treatment with</str><str>therapeutic doses of sodium warfarin (Coumadin®) or coumadin derivatives. Low doses</str><str>of Coumadin® (e.g. ≤ 2.0 mg/day) to maintain line patency (if applicable) is allowed.</str><str>Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or</str><str>who have not recovered from side effects of such therapy</str><str>Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)</str><str>not using an effective method of birth control. WOCBP are defined as sexually mature</str><str>women who have not undergone a hysterectomy or who have not been naturally</str><str>postmenopausal for at least 12 consecutive months (i.e., who has had menses any time</str><str>in the preceding 12 consecutive months). Women of childbearing potential must have a</str><str>negative serum pregnancy test within 24hrs of receiving the first dose of study</str><str>medication.</str><str>Male patients whose sexual partners are WOCBP not using effective birth control</str><str>Patients with a prior malignancy with in the last 5 years (except for basal  or</str><str>quamous cell carcinoma, or in situ cancer of the cervix)</str><str>Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis</str><str>C; baseline testing for HIV and hepatitis C is not required</str><str>Patients with any significant history of non-compliance to medical regimens or</str><str>unwilling or unable to comply with the instructions given to him/her by the study</str><str>taff.</str><str>No concomitant use of bisphosphonates is allowed</str></arr><str name="display_conditions">Multiple Myeloma</str><str name="django_ct">txdb.trial</str><str name="django_id">84828</str><str name="gender">Both</str><bool name="has_investigator">true</bool><str name="id">txdb.trial.84828</str><bool name="is_featured">false</bool><bool name="isactive">true</bool><bool name="isusersubmitted">true</bool><date name="lchangetime">2010-12-13T00:00:00Z</date><long name="maxage">100</long><long name="minage">18</long><str name="nctIdentifier">NCT00891033</str><long name="phase">1</long><float name="rank">0.9</float><str name="show_transplant_trials">no</str><arr name="sitenames"><str>Huntsman Cancer Hospital</str></arr><arr name="state"><str>UT</str></arr><str name="study_type">Interventional</str><str name="title">Panobinostat/Velcade in Multiple Myeloma</str><arr name="treatment_name"><str>Bortezomib (Velcade)</str><str>Panobinostat</str></arr><arr name="treatment_status"><str>multiple_relapse</str><str>first_relapse</str><str>Refractory</str></arr><str name="weburl">multiple-myeloma-panobinostatvelcade-multiple-myeloma</str><arr name="zipcode"><str>84112</str></arr></doc><doc><arr name="city"><str>Salt Lake City</str></arr><arr name="conditions"><str>Multiple Myeloma</str><str>Multiple Myeloma and Plasma Cell Neoplasm</str><str>Multiple Myeloma And Immunoproliferative Neoplasms</str><str>Mult Myelm W/O Remission</str><str>Mult Myelm W Remission</str><str>Multiple Myeloma Stage I</str><str>Multiple Myeloma Stage Ii</str><str>Multiple Myeloma Stage Iii</str><str>Fgfr3/Igh Fusion</str><str>Increased Risk For Multiple Myeloma</str><str>Lig4, Ala3val</str><str>Lig4, Thr9ile</str><str>m protein, multiple myeloma</str><str>prevention of multiple myeloma</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; stage ii or higher (for use in a medicare-approved demonstration project)</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; extent of disease unknown, </str><str>whsc1 protein, human</str><str>trappc1 protein, human</str><str>multiple myeloma patients with no documentation of prescribed or received intravenous bisphosphonate therapy</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; smoldering, stage i (for use in a medicare-approved demonstration project)</str><str>myeov protein, human</str><str>Multiple Myeloma Bone Disease</str><str>Refractory Multiple Myeloma</str><str>Hematologic Malignancies, Multiple Myeloma, Lymphoma</str><str>Relapsed or Refractory Multiple Myeloma</str><str>Smoldering Multiple Myeloma</str><str>Relapsed Multiple Myeloma</str><str>Multiple Myeloma With Plasmacytoma</str><str>Relapsed and Refractory Multiple Myeloma</str><str>Hodgkin's Disease or Multiple Myeloma</str><str>Relapsed and/or Refractory Multiple Myeloma</str></arr><arr name="coordinates"><str>40.76784,-111.83805</str></arr><arr name="criteria"><str>Subjects must have ≥ 3 x 106 CD34 cell/kg in storage for this study.</str><str>Subjects must have symptomatic multiple myeloma that, in the opinion of the enrolling</str><str>physician, requires treatment.</str><str>Subjects must be at least 65 years of age and/or diagnosed with renal insufficiency,</str><str>defined as serum creatinine ≥3mg/dL or a creatinine clearance of less than</str><str>30mL/minute.</str><str>Subjects must not have a history of chronic obstructive or chronic restrictive</str><str>pulmonary disease.  Subjects must demonstrate adequate pulmonary function studies</str><str>defined as ≥50% of predicted on mechanical aspects (FEV1, FVC) and diffusion capacity</str><str>(DLCO).</str><str>Subjects must demonstrate adequate cardiac function (≥40% LVEF on ECHO or MUGA).</str><str>Subjects must demonstrate adequate liver functions with direct bilirubin and</str><str>transaminase levels no higher than 1.5 times the institutional upper limit of normal.</str><str>Subjects must have at least one evaluable myeloma marker by which to judge response:</str><str>erum M protein &gt;1g/dL, urine M &gt;1g/24-hours, free light chains in the serum more</str><str>than four times the upper limit of normal with abnormal free light chain ratio, bone</str><str>marrow plasmacytosis with &gt;20% plasma cells, extramedullary plasmacytosis, or</str><str>MRI/FDG-PET/CT scan demonstrating focal lesions due to myeloma.</str><str>Subjects must have a SWOG performance score of 0-2 unless due to myeloma-related bone</str><str>pain.</str><str>Subjects must be informed of the investigational nature of the study and must sign an</str><str>IRB-approved informed consent in accordance with institutional and federal</str><str>guidelines.</str><str>Female participants of child-bearing potential must have a negative pregnancy test</str><str>documented within 10 days of enrollment.</str><str>Subjects must not have serum transaminases &gt;1.5 times the upper limit of normal</str><str>and/or a direct bilirubin &gt;1.5 time the institutional upper limit of normal..</str><str>Subjects must not be HIV positive or have active Hepatitis B or Hepatitis C</str><str>infection. If serology antibody studies are positive, a quantitative PCR must be done</str><str>to confirm.</str><str>Subjects must not have a prior malignancy in which life expectancy, which in the</str><str>opinion of the investigator, is more likely to be determined by the prior malignancy</str><str>than the myeloma. Patients must not be currently receiving therapy for the prior</str><str>malignancy.</str><str>Subjects must not be pregnant or nursing. Women and men of reproductive potential may</str><str>not participate unless they agree to use an effective contraceptive method.</str><str>Patients who have &lt; 3 million CD34 cells/kg stored for this protocol.</str><str>Subjects must have ≥ 3 x 106 CD34 cell/kg in storage for this study.</str><str>Subjects must have symptomatic multiple myeloma that, in the opinion of the enrolling</str><str>physician, requires treatment.</str><str>Subjects must be at least 65 years of age and/or diagnosed with renal insufficiency,</str><str>defined as serum creatinine ≥3mg/dL or a creatinine clearance of less than</str><str>30mL/minute.</str><str>Subjects must not have a history of chronic obstructive or chronic restrictive</str><str>pulmonary disease.  Subjects must demonstrate adequate pulmonary function studies</str><str>defined as ≥50% of predicted on mechanical aspects (FEV1, FVC) and diffusion capacity</str><str>(DLCO).</str><str>Subjects must demonstrate adequate cardiac function (≥40% LVEF on ECHO or MUGA).</str><str>Subjects must demonstrate adequate liver functions with direct bilirubin and</str><str>transaminase levels no higher than 1.5 times the institutional upper limit of normal.</str><str>Subjects must have at least one evaluable myeloma marker by which to judge response:</str><str>erum M protein &gt;1g/dL, urine M &gt;1g/24-hours, free light chains in the serum more</str><str>than four times the upper limit of normal with abnormal free light chain ratio, bone</str><str>marrow plasmacytosis with &gt;20% plasma cells, extramedullary plasmacytosis, or</str><str>MRI/FDG-PET/CT scan demonstrating focal lesions due to myeloma.</str><str>Subjects must have a SWOG performance score of 0-2 unless due to myeloma-related bone</str><str>pain.</str><str>Subjects must be informed of the investigational nature of the study and must sign an</str><str>IRB-approved informed consent in accordance with institutional and federal</str><str>guidelines.</str><str>Female participants of child-bearing potential must have a negative pregnancy test</str><str>documented within 10 days of enrollment.</str><str>Subjects must not have serum transaminases &gt;1.5 times the upper limit of normal</str><str>and/or a direct bilirubin &gt;1.5 time the institutional upper limit of normal..</str><str>Subjects must not be HIV positive or have active Hepatitis B or Hepatitis C</str><str>infection. If serology antibody studies are positive, a quantitative PCR must be done</str><str>to confirm.</str><str>Subjects must not have a prior malignancy in which life expectancy, which in the</str><str>opinion of the investigator, is more likely to be determined by the prior malignancy</str><str>than the myeloma. Patients must not be currently receiving therapy for the prior</str><str>malignancy.</str><str>Subjects must not be pregnant or nursing. Women and men of reproductive potential may</str><str>not participate unless they agree to use an effective contraceptive method.</str><str>Patients who have &lt; 3 million CD34 cells/kg stored for this protocol.</str><str>Subjects must have ≥ 3 x 106 CD34 cell/kg in storage for this study.</str><str>Subjects must have symptomatic multiple myeloma that, in the opinion of the enrolling</str><str>physician, requires treatment.</str><str>Subjects must be at least 65 years of age and/or diagnosed with renal insufficiency,</str><str>defined as serum creatinine ≥3mg/dL or a creatinine clearance of less than</str><str>30mL/minute.</str><str>Subjects must not have a history of chronic obstructive or chronic restrictive</str><str>pulmonary disease.  Subjects must demonstrate adequate pulmonary function studies</str><str>defined as ≥50% of predicted on mechanical aspects (FEV1, FVC) and diffusion capacity</str><str>(DLCO).</str><str>Subjects must demonstrate adequate cardiac function (≥40% LVEF on ECHO or MUGA).</str><str>Subjects must demonstrate adequate liver functions with direct bilirubin and</str><str>transaminase levels no higher than 1.5 times the institutional upper limit of normal.</str><str>Subjects must have at least one evaluable myeloma marker by which to judge response:</str><str>erum M protein &gt;1g/dL, urine M &gt;1g/24-hours, free light chains in the serum more</str><str>than four times the upper limit of normal with abnormal free light chain ratio, bone</str><str>marrow plasmacytosis with &gt;20% plasma cells, extramedullary plasmacytosis, or</str><str>MRI/FDG-PET/CT scan demonstrating focal lesions due to myeloma.</str><str>Subjects must have a SWOG performance score of 0-2 unless due to myeloma-related bone</str><str>pain.</str><str>Subjects must be informed of the investigational nature of the study and must sign an</str><str>IRB-approved informed consent in accordance with institutional and federal</str><str>guidelines.</str><str>Female participants of child-bearing potential must have a negative pregnancy test</str><str>documented within 10 days of enrollment.</str><str>Subjects must not have serum transaminases &gt;1.5 times the upper limit of normal</str><str>and/or a direct bilirubin &gt;1.5 time the institutional upper limit of normal..</str><str>Subjects must not be HIV positive or have active Hepatitis B or Hepatitis C</str><str>infection. If serology antibody studies are positive, a quantitative PCR must be done</str><str>to confirm.</str><str>Subjects must not have a prior malignancy in which life expectancy, which in the</str><str>opinion of the investigator, is more likely to be determined by the prior malignancy</str><str>than the myeloma. Patients must not be currently receiving therapy for the prior</str><str>malignancy.</str><str>Subjects must not be pregnant or nursing. Women and men of reproductive potential may</str><str>not participate unless they agree to use an effective contraceptive method.</str><str>Patients who have &lt; 3 million CD34 cells/kg stored for this protocol.</str><str>Subjects must have ≥ 3 x 106 CD34 cell/kg in storage for this study.</str><str>Subjects must have symptomatic multiple myeloma that, in the opinion of the enrolling</str><str>physician, requires treatment.</str><str>Subjects must be at least 65 years of age and/or diagnosed with renal insufficiency,</str><str>defined as serum creatinine ≥3mg/dL or a creatinine clearance of less than</str><str>30mL/minute.</str><str>Subjects must not have a history of chronic obstructive or chronic restrictive</str><str>pulmonary disease.  Subjects must demonstrate adequate pulmonary function studies</str><str>defined as ≥50% of predicted on mechanical aspects (FEV1, FVC) and diffusion capacity</str><str>(DLCO).</str><str>Subjects must demonstrate adequate cardiac function (≥40% LVEF on ECHO or MUGA).</str><str>Subjects must demonstrate adequate liver functions with direct bilirubin and</str><str>transaminase levels no higher than 1.5 times the institutional upper limit of normal.</str><str>Subjects must have at least one evaluable myeloma marker by which to judge response:</str><str>erum M protein &gt;1g/dL, urine M &gt;1g/24-hours, free light chains in the serum more</str><str>than four times the upper limit of normal with abnormal free light chain ratio, bone</str><str>marrow plasmacytosis with &gt;20% plasma cells, extramedullary plasmacytosis, or</str><str>MRI/FDG-PET/CT scan demonstrating focal lesions due to myeloma.</str><str>Subjects must have a SWOG performance score of 0-2 unless due to myeloma-related bone</str><str>pain.</str><str>Subjects must be informed of the investigational nature of the study and must sign an</str><str>IRB-approved informed consent in accordance with institutional and federal</str><str>guidelines.</str><str>Female participants of child-bearing potential must have a negative pregnancy test</str><str>documented within 10 days of enrollment.</str><str>Subjects must not have serum transaminases &gt;1.5 times the upper limit of normal</str><str>and/or a direct bilirubin &gt;1.5 time the institutional upper limit of normal..</str><str>Subjects must not be HIV positive or have active Hepatitis B or Hepatitis C</str><str>infection. If serology antibody studies are positive, a quantitative PCR must be done</str><str>to confirm.</str><str>Subjects must not have a prior malignancy in which life expectancy, which in the</str><str>opinion of the investigator, is more likely to be determined by the prior malignancy</str><str>than the myeloma. Patients must not be currently receiving therapy for the prior</str><str>malignancy.</str><str>Subjects must not be pregnant or nursing. Women and men of reproductive potential may</str><str>not participate unless they agree to use an effective contraceptive method.</str><str>Patients who have &lt; 3 million CD34 cells/kg stored for this protocol.</str><str>Subjects must have ≥ 3 x 106 CD34 cell/kg in storage for this study.</str><str>Subjects must have symptomatic multiple myeloma that, in the opinion of the enrolling</str><str>physician, requires treatment.</str><str>Subjects must be at least 65 years of age and/or diagnosed with renal insufficiency,</str><str>defined as serum creatinine ≥3mg/dL or a creatinine clearance of less than</str><str>30mL/minute.</str><str>Subjects must not have a history of chronic obstructive or chronic restrictive</str><str>pulmonary disease.  Subjects must demonstrate adequate pulmonary function studies</str><str>defined as ≥50% of predicted on mechanical aspects (FEV1, FVC) and diffusion capacity</str><str>(DLCO).</str><str>Subjects must demonstrate adequate cardiac function (≥40% LVEF on ECHO or MUGA).</str><str>Subjects must demonstrate adequate liver functions with direct bilirubin and</str><str>transaminase levels no higher than 1.5 times the institutional upper limit of normal.</str><str>Subjects must have at least one evaluable myeloma marker by which to judge response:</str><str>erum M protein &gt;1g/dL, urine M &gt;1g/24-hours, free light chains in the serum more</str><str>than four times the upper limit of normal with abnormal free light chain ratio, bone</str><str>marrow plasmacytosis with &gt;20% plasma cells, extramedullary plasmacytosis, or</str><str>MRI/FDG-PET/CT scan demonstrating focal lesions due to myeloma.</str><str>Subjects must have a SWOG performance score of 0-2 unless due to myeloma-related bone</str><str>pain.</str><str>Subjects must be informed of the investigational nature of the study and must sign an</str><str>IRB-approved informed consent in accordance with institutional and federal</str><str>guidelines.</str><str>Female participants of child-bearing potential must have a negative pregnancy test</str><str>documented within 10 days of enrollment.</str><str>Subjects must not have serum transaminases &gt;1.5 times the upper limit of normal</str><str>and/or a direct bilirubin &gt;1.5 time the institutional upper limit of normal..</str><str>Subjects must not be HIV positive or have active Hepatitis B or Hepatitis C</str><str>infection. If serology antibody studies are positive, a quantitative PCR must be done</str><str>to confirm.</str><str>Subjects must not have a prior malignancy in which life expectancy, which in the</str><str>opinion of the investigator, is more likely to be determined by the prior malignancy</str><str>than the myeloma. Patients must not be currently receiving therapy for the prior</str><str>malignancy.</str><str>Subjects must not be pregnant or nursing. Women and men of reproductive potential may</str><str>not participate unless they agree to use an effective contraceptive method.</str><str>Patients who have &lt; 3 million CD34 cells/kg stored for this protocol.</str><str>Subjects must have ≥ 3 x 106 CD34 cell/kg in storage for this study.</str><str>Subjects must have symptomatic multiple myeloma at their new patient consult at HCI</str><str>that, in the opinion of the enrolling physician, requires treatment.</str><str>Subjects must be at least 65 years of age and/or diagnosed with renal insufficiency,</str><str>defined as serum creatinine ≥3mg/dL or a creatinine clearance of less than</str><str>30mL/minute.</str><str>Subjects must not have a history of chronic obstructive or chronic restrictive</str><str>pulmonary disease.  Subjects must demonstrate adequate pulmonary function studies</str><str>defined as ≥50% of predicted on mechanical aspects (FEV1, FVC) and diffusion capacity</str><str>(DLCO).</str><str>Subjects must demonstrate adequate cardiac function (≥40% LVEF on ECHO or MUGA).</str><str>Subjects must demonstrate adequate liver functions with total bilirubin and</str><str>transaminase levels no higher than 1.5 times the institutional upper limit of normal.</str><str>(If total bilirubin is &gt; 1.5 times the upper limit of normal, a direct bilirubin</str><str>needs to be assessed. Subject eligible as long as the direct bilirubin is not  &gt; 1.5</str><str>times the upper limit of normal)</str><str>Subjects must have at least one evaluable myeloma marker by which to judge response:</str><str>erum M protein &gt;1g/dL, free light chains in the serum that more than four times the</str><str>upper limit of normal, urine M protein of  ≥ 500 mg, urine free light chains of ≥ 500</str><str>mg/day, bone marrow plasmacytosis with &gt;20% plasma cells, extramedullary</str><str>plasmacytosis, or MRI/FDG-PET/CT scan demonstrating 1 or more focal lesions due to</str><str>myeloma.</str><str>Subjects must have a SWOG performance score of 0-2 unless due to myeloma-related bone</str><str>pain.</str><str>Subjects must be informed of the investigational nature of the study and must sign an</str><str>IRB-approved informed consent in accordance with institutional and federal</str><str>guidelines.</str><str>Female participants of child-bearing potential must have a negative pregnancy test</str><str>documented within 10 days of enrollment.</str><str>Subjects must not have serum transaminases &gt;1.5 times the upper limit of normal</str><str>and/or a direct bilirubin &gt;1.5 time the institutional upper limit of normal (direct</str><str>bilirubin to be assessed only if the total bilirubin is &gt; 1.5 times the upper limit</str><str>of normal)</str><str>Subjects must not be HIV positive or have active Hepatitis B or Hepatitis C</str><str>infection. If serology antibody studies are positive, a quantitative PCR must be done</str><str>to confirm.</str><str>Subjects must not have a prior malignancy in which life expectancy, which in the</str><str>opinion of the investigator, is more likely to be determined by the prior malignancy</str><str>than the myeloma. Patients must not be currently receiving therapy for the prior</str><str>malignancy.</str><str>Subjects must not have had a prior autologous or allogeneic bone marrow transplant.</str><str>Subjects must not be pregnant or nursing. Women and men of reproductive potential may</str><str>not participate unless they agree to use an effective contraceptive method.</str><str>Patients who have &lt; 3 million CD34 cells/kg stored for this protocol.</str></arr><str name="display_conditions">Multiple Myeloma</str><str name="django_ct">txdb.trial</str><str name="django_id">90201</str><str name="gender">Both</str><bool name="has_investigator">true</bool><str name="id">txdb.trial.90201</str><bool name="is_featured">false</bool><bool name="isactive">true</bool><bool name="isusersubmitted">true</bool><date name="lchangetime">2011-02-18T00:00:00Z</date><long name="maxage">100</long><long name="minage">18</long><str name="nctIdentifier">NCT00934232</str><long name="phase">0</long><float name="rank">0.9</float><str name="show_transplant_trials">no</str><arr name="sitenames"><str>Huntsman Cancer Hospital</str></arr><arr name="state"><str>UT</str></arr><str name="study_type">Interventional</str><str name="title">Busulfan in Multiple Myeloma</str><arr name="treatment_name"><str>busulfan</str></arr><str name="weburl">multiple-myeloma-busulfan-multiple-myeloma</str><arr name="zipcode"><str>84112</str></arr></doc><doc><arr name="city"><str>Houston</str></arr><arr name="conditions"><str>Multiple Myeloma</str></arr><arr name="coordinates"><str>29.704584,-95.40466</str></arr><arr name="criteria"><str>Recipient for vaccine production: Multiple Myeloma who have received or are planned</str><str>to receive an allogeneic progenitor cell transplant from a HLA compatible related</str><str>donor (either 6/6 or 5/6 related donor).</str><str>Recipient for vaccine production: Have evidence of persistent or relapsing disease as</str><str>demonstrated by persistent serum peak (by either standard protein electrophoresis,</str><str>immune fixation or free light chain assays), or marrow infiltration. Serum peak must</str><str>be greater than 0.2 gm/dl and represent more than 70% of the specific immunoglobulin</str><str>ubtype. Patients who have adequate amount of monoclonal idiotype protein previously</str><str>cryopreserved on prior departmental laboratory protocols are also eligible to be</str><str>registered for vaccine production using the cryopreserved samples</str><str>Recipient to receive vaccine greater or equal than 3 months post allogeneic</str><str>transplant and with 5% or greater donor cell engraftment.</str><str>Recipient: Age up to 70 years.</str><str>Recipient: Zubrod PS&lt;/= to 2.</str><str>Recipient: On a prednisone or prednisone equivalent dose of no more than 10 mg every</str><str>other day. Tacrolimus and cyclosporine levels must be less than 5 ng/dl or &lt; 100</str><str>ng/dl respectively.</str><str>Recipient: Have no uncontrolled GVHD.</str><str>Recipient: Have no serious organ dysfunction as defined by serum creatinine &lt;/= to</str><str>5 mg/dL, serum bilirubin &lt;/= to 3 X upper limit of normal, SGPT &lt;/= to 4 X upper</str><str>limit of normal.</str><str>Recipient: HIV-negative, hepatitis B negative, hepatitis C negative.</str><str>Recipient: Negative Beta HCG test in a woman with child bearing potential defined as</str><str>not post-menopausal for 12 months or no previous surgical sterilization) and willing</str><str>to use an effective contraceptive measure while on study. Not lactating</str><str>Recipient: Able to sign written informed consent.</str><str>Donor: Able to sign written informed consent and be willing to provide donor</str><str>lymphocytes.</str><str>Donor: Donor age 18 - 75 years.</str><str>Donor: No physical contraindications to lymphocyte collection(i.e. severe</str><str>atherosclerosis, auto-immune disease, cerebrovascular accident, prior malignancy less</str><str>than 5 years ago other than non-melanoma skin cancer treated with surgery. Donors</str><str>with severe atherosclerosis by history will receive a cardiology consult and be</str><str>judged eligible on a case by case basis.</str><str>Donor: Donors must be HIV negative, HbsAg negative, and Hepatitis C antibody</str><str>negative. This is to prevent the possible transmission of these infections to the</str><str>recipient.</str><str>Donor: Negative Beta HCG test in a woman with child bearing potential (not post-</str><str>menopausal for 12 months or no previous surgical sterilization) must use an effective</str><str>method of contraceptive until at least 1 month after lymphocyte collection.</str><str>Recipient for vaccine production: Multiple Myeloma who have received or are planned</str><str>to receive an allogeneic progenitor cell transplant from a HLA compatible related</str><str>donor (either 6/6 or 5/6 related donor).</str><str>Recipient for vaccine production: Have evidence of persistent or relapsing disease as</str><str>demonstrated by persistent serum peak (by either standard protein electrophoresis,</str><str>immune fixation or free light chain assays), or marrow infiltration. Serum peak must</str><str>be greater than 0.2 gm/dl and represent more than 70% of the specific immunoglobulin</str><str>ubtype. Patients who have adequate amount of monoclonal idiotype protein previously</str><str>cryopreserved on prior departmental laboratory protocols are also eligible to be</str><str>registered for vaccine production using the cryopreserved samples</str><str>Recipient to receive vaccine greater or equal than 3 months post allogeneic</str><str>transplant and with 5% or greater donor cell engraftment.</str><str>Recipient: Age up to 70 years.</str><str>Recipient: Zubrod PS&lt;/= to 2.</str><str>Recipient: On a prednisone or prednisone equivalent dose of no more than 10 mg every</str><str>other day. Tacrolimus and cyclosporine levels must be less than 5 ng/dl or &lt; 100</str><str>ng/dl respectively.</str><str>Recipient: Have no uncontrolled GVHD.</str><str>Recipient: Have no serious organ dysfunction as defined by serum creatinine &lt;/= to</str><str>5 mg/dL, serum bilirubin &lt;/= to 3 X upper limit of normal, SGPT &lt;/= to 4 X upper</str><str>limit of normal.</str><str>Recipient: HIV-negative, hepatitis B negative, hepatitis C negative.</str><str>Recipient: Negative Beta HCG test in a woman with child bearing potential defined as</str><str>not post-menopausal for 12 months or no previous surgical sterilization) and willing</str><str>to use an effective contraceptive measure while on study. Not lactating</str><str>Recipient: Able to sign written informed consent.</str><str>Donor: Able to sign written informed consent and be willing to provide donor</str><str>lymphocytes.</str><str>Donor: Donor age 18 - 75 years.</str><str>Donor: No physical contraindications to lymphocyte collection(i.e. severe</str><str>atherosclerosis, auto-immune disease, cerebrovascular accident, prior malignancy less</str><str>than 5 years ago other than non-melanoma skin cancer treated with surgery. Donors</str><str>with severe atherosclerosis by history will receive a cardiology consult and be</str><str>judged eligible on a case by case basis.</str><str>Donor: Donors must be HIV negative, HbsAg negative, and Hepatitis C antibody</str><str>negative. This is to prevent the possible transmission of these infections to the</str><str>recipient.</str><str>Donor: Negative Beta HCG test in a woman with child bearing potential (not post-</str><str>menopausal for 12 months or no previous surgical sterilization) must use an effective</str><str>method of contraceptive until at least 1 month after lymphocyte collection.</str><str>Recipient for vaccine production: Multiple Myeloma who have received or are planned</str><str>to receive an allogeneic progenitor cell transplant from a HLA compatible related</str><str>donor (either 6/6 or 5/6 related donor).</str><str>Recipient for vaccine production: Have evidence of persistent or relapsing disease as</str><str>demonstrated by persistent serum peak (by either standard protein electrophoresis,</str><str>immune fixation or free light chain assays), or marrow infiltration. Serum peak must</str><str>be greater than 0.2 gm/dl and represent more than 70% of the specific immunoglobulin</str><str>ubtype. Patients who have adequate amount of monoclonal idiotype protein previously</str><str>cryopreserved on prior departmental laboratory protocols are also eligible to be</str><str>registered for vaccine production using the cryopreserved samples</str><str>Recipient to receive vaccine greater or equal than 3 months post allogeneic</str><str>transplant and with 5% or greater donor cell engraftment.</str><str>Recipient: Age up to 70 years.</str><str>Recipient: Zubrod PS&lt;/= to 2.</str><str>Recipient: On a prednisone or prednisone equivalent dose of no more than 10 mg every</str><str>other day. Tacrolimus and cyclosporine levels must be less than 5 ng/dl or &lt; 100</str><str>ng/dl respectively.</str><str>Recipient: Have no uncontrolled GVHD.</str><str>Recipient: Have no serious organ dysfunction as defined by serum creatinine &lt;/= to</str><str>5 mg/dL, serum bilirubin &lt;/= to 3 X upper limit of normal, SGPT &lt;/= to 4 X upper</str><str>limit of normal.</str><str>Recipient: HIV-negative, hepatitis B negative, hepatitis C negative.</str><str>Recipient: Negative Beta HCG test in a woman with child bearing potential defined as</str><str>not post-menopausal for 12 months or no previous surgical sterilization) and willing</str><str>to use an effective contraceptive measure while on study. Not lactating</str><str>Recipient: Able to sign written informed consent.</str><str>Donor: Able to sign written informed consent and be willing to provide donor</str><str>lymphocytes.</str><str>Donor: Donor age 18 - 75 years.</str><str>Donor: No physical contraindications to lymphocyte collection(i.e. severe</str><str>atherosclerosis, auto-immune disease, cerebrovascular accident, prior malignancy less</str><str>than 5 years ago other than non-melanoma skin cancer treated with surgery. Donors</str><str>with severe atherosclerosis by history will receive a cardiology consult and be</str><str>judged eligible on a case by case basis.</str><str>Donor: Donors must be HIV negative, HbsAg negative, and Hepatitis C antibody</str><str>negative. This is to prevent the possible transmission of these infections to the</str><str>recipient.</str><str>Donor: Negative Beta HCG test in a woman with child bearing potential (not post-</str><str>menopausal for 12 months or no previous surgical sterilization) must use an effective</str><str>method of contraceptive until at least 1 month after lymphocyte collection.</str><str>Recipient for vaccine production: Multiple Myeloma who have received or are planned</str><str>to receive an allogeneic progenitor cell transplant from a HLA compatible related</str><str>donor (either 6/6 or 5/6 related donor).</str><str>Recipient for vaccine production: Have evidence of persistent or relapsing disease as</str><str>demonstrated by persistent serum peak (by either standard protein electrophoresis,</str><str>immune fixation or free light chain assays), or marrow infiltration. Serum peak must</str><str>be greater than 0.2 gm/dl and represent more than 70% of the specific immunoglobulin</str><str>ubtype. Patients who have adequate amount of monoclonal idiotype protein previously</str><str>cryopreserved on prior departmental laboratory protocols are also eligible to be</str><str>registered for vaccine production using the cryopreserved samples</str><str>Recipient to receive vaccine greater or equal than 3 months post allogeneic</str><str>transplant and with 5% or greater donor cell engraftment.</str><str>Recipient: Age up to 70 years.</str><str>Recipient: Zubrod PS&lt;/= to 2.</str><str>Recipient: On a prednisone or prednisone equivalent dose of no more than 10 mg every</str><str>other day. Tacrolimus and cyclosporine levels must be less than 5 ng/dl or &lt; 100</str><str>ng/dl respectively.</str><str>Recipient: Have no uncontrolled GVHD.</str><str>Recipient: Have no serious organ dysfunction as defined by serum creatinine &lt;/= to</str><str>5 mg/dL, serum bilirubin &lt;/= to 3 X upper limit of normal, SGPT &lt;/= to 4 X upper</str><str>limit of normal.</str><str>Recipient: HIV-negative, hepatitis B negative, hepatitis C negative.</str><str>Recipient: Negative Beta HCG test in a woman with child bearing potential defined as</str><str>not post-menopausal for 12 months or no previous surgical sterilization) and willing</str><str>to use an effective contraceptive measure while on study. Not lactating</str><str>Recipient: Able to sign written informed consent.</str><str>Donor: Able to sign written informed consent and be willing to provide donor</str><str>lymphocytes.</str><str>Donor: Donor age 18 - 75 years.</str><str>Donor: No physical contraindications to lymphocyte collection(i.e. severe</str><str>atherosclerosis, auto-immune disease, cerebrovascular accident, prior malignancy less</str><str>than 5 years ago other than non-melanoma skin cancer treated with surgery. Donors</str><str>with severe atherosclerosis by history will receive a cardiology consult and be</str><str>judged eligible on a case by case basis.</str><str>Donor: Donors must be HIV negative, HbsAg negative, and Hepatitis C antibody</str><str>negative. This is to prevent the possible transmission of these infections to the</str><str>recipient.</str><str>Donor: Negative Beta HCG test in a woman with child bearing potential (not post-</str><str>menopausal for 12 months or no previous surgical sterilization) must use an effective</str><str>method of contraceptive until at least 1 month after lymphocyte collection.</str><str>Recipient: Patient with IgG1, IgG2, or IgG4 Multiple Myeloma who has received or</str><str>planning to receive an allogeneic progenitor cell transplant from a HLA compatible</str><str>related donor (either 6/6 or 5/6 related donor).</str><str>Recipient: Have evidence of persistent or relapsing disease as demonstrated by</str><str>persistent serum peak (by either standard protein electrophoresis, immune fixation or</str><str>free light chain assays) or marrow infiltration. Serum peak must be greater or equal</str><str>than 0.2 gm/dl and represent more than 70% of the specific immunoglobulin subtype.</str><str>Patients who have adequate amount of monoclonal idiotype protein previously</str><str>cryopreserved on prior departmental laboratory protocols are also eligible to be</str><str>registered for vaccine production using the cryopreserved samples.</str><str>Recipient: Able to sign written informed consent.</str><str>Recipient: Age up to 70 years.</str><str>Recipient: Zubrod PS &gt;/=2.</str><str>Recipient: Have no serious organ dysfunction as defined by serum creatinine &lt;2.5</str><str>mg/dL, serum bilirubin &lt;3 x upper limit of normal, SGPT &lt;4 x upper limit of normal.</str><str>Recipient: Donor infectious disease panel: HBV, HCV, HIV, and NAT (nucleic acid</str><str>test). This is to prevent the possible transmission of these infections to the</str><str>recipient.</str><str>Recipient: Negative serum Beta HCG test in a women with child bearing potential (not</str><str>post-menopausal for 12 months or no previous surgical sterilization) and willing to</str><str>use an effective contraceptive measure while on study. Mothers should not breastfeed</str><str>during the study.</str><str>Donor: Able to sign written informed consent and be willing to provide donor</str><str>lymphocytes.</str><str>Donor: Age 18 - 75 years</str><str>Donor: No physical contraindications to lymphocyte collection (i.e. severe</str><str>atherosclerosis, auto-immune disease, cerebrovascular accident, prior malignancy less</str><str>than 5 years ago other than non-melanoma skin cancer treated with surgery). Donors</str><str>with severe atherosclerosis by history will receive a cardiology consult and be</str><str>judged eligible on a case by case basis.</str><str>Donor: Donor infectious disease panel: HBV, HCV, HIV, and NAT. This is to prevent the</str><str>possible transmission of these infections to the recipient.</str><str>Donor: Negative serum Beta HCG test in a woman with child bearing potential (not</str><str>post-menopausal for 12 months or no previous surgical sterilization) must use an</str><str>effective method of contraception until at least 1 month after lymphocyte collection.</str><str>Mothers should not breastfeed during the study.</str><str>1) Recipient with IGg3 Multiple Myeloma.</str><str>Recipient: Patient with IgG1, IgG2, or IgG4 Multiple Myeloma who has received or</str><str>planning to receive an allogeneic progenitor cell transplant from a HLA compatible</str><str>related donor (either 6/6 or 5/6 related donor).</str><str>Recipient: Have evidence of persistent or relapsing disease as demonstrated by</str><str>persistent serum peak (by either standard protein electrophoresis, immune fixation or</str><str>free light chain assays) or marrow infiltration. Serum peak must be greater or equal</str><str>than 0.2 gm/dl and represent more than 70% of the specific immunoglobulin subtype.</str><str>Patients who have adequate amount of monoclonal idiotype protein previously</str><str>cryopreserved on prior departmental laboratory protocols are also eligible to be</str><str>registered for vaccine production using the cryopreserved samples.</str><str>Recipient: Able to sign written informed consent.</str><str>Recipient: Age up to 70 years.</str><str>Recipient: Zubrod PS &gt;/=2.</str><str>Recipient: Have no serious organ dysfunction as defined by serum creatinine &lt;2.5</str><str>mg/dL, serum bilirubin &lt;3 x upper limit of normal, SGPT &lt;4 x upper limit of normal.</str><str>Recipient: Negative donor infectious disease panel: Hepatitis B surface antigen</str><str>(HBsAg), Anti-Hepatitis B core antibody (HBcAb), Anti-Hepatitis C Virus antibody (HCV</str><str>Ab), Anti-Human Immunodeficiency Virus (HIV) antibody (HIV 1/2 type O Ab), Anti-Human</str><str>T cell lymphotrophic Virus (HTLV) antibody (HTLV I/II Ab), Rapid Plasma Reagen (RPR),</str><str>Cytomegalovirus antibody (CMV), HCV/HIV Nucleic Acid Test, West Nile Virus Nucleic</str><str>Acid Test, Sickledex, T Cruzi AB. Additional tests shall be performed as required to</str><str>assess the possibility of transmission of other infectious or non-infectious</str><str>diseases.</str><str>Recipient: Negative serum Beta HCG test in a women with child bearing potential (not</str><str>post-menopausal for 12 months or no previous surgical sterilization) and willing to</str><str>use an effective contraceptive measure while on study. Mothers should not breastfeed</str><str>during the study.</str><str>Donor: Able to sign written informed consent and be willing to provide donor</str><str>lymphocytes.</str><str>Donor: Age 18 - 75 years</str><str>Donor: No physical contraindications to lymphocyte collection (i.e. severe</str><str>atherosclerosis, auto-immune disease, cerebrovascular accident, prior malignancy less</str><str>than 5 years ago other than non-melanoma skin cancer treated with surgery). Donors</str><str>with severe atherosclerosis by history will receive a cardiology consult and be</str><str>judged eligible on a case by case basis.</str><str>Donor: Negative donor infectious disease panel: Hepatitis B surface antigen (HBsAg),</str><str>Anti-Hepatitis B core antibody (HBcAb), Anti-Hepatitis C Virus antibody (HCV Ab),</str><str>Anti-Human Immunodeficiency Virus (HIV) antibody (HIV 1/2 type O Ab), Anti-Human T</str><str>cell lymphotrophic Virus (HTLV) antibody (HTLV I/II Ab), Rapid Plasma Reagen (RPR),</str><str>Cytomegalovirus antibody (CMV), HCV/HIV Nucleic Acid test. Additional tests shall be</str><str>performed as required to assess the possibility of transmission of other infectious</str><str>or non-infectious diseases.</str><str>Donor: Negative serum Beta HCG test in a woman with child bearing potential (not</str><str>post-menopausal for 12 months or no previous surgical sterilization) must use an</str><str>effective method of contraception until at least 1 month after lymphocyte collection.</str><str>Mothers should not breastfeed during the study.</str><str>1) Recipient with IGg3 Multiple Myeloma.</str></arr><str name="display_conditions">Myeloma</str><str name="django_ct">txdb.trial</str><str name="django_id">93610</str><str name="gender">Both</str><bool name="has_investigator">true</bool><str name="id">txdb.trial.93610</str><bool name="is_featured">false</bool><bool name="isactive">true</bool><bool name="isusersubmitted">true</bool><date name="lchangetime">2012-01-19T00:00:00Z</date><long name="maxage">70</long><long name="minage">18</long><str name="nctIdentifier">NCT01174082</str><long name="phase">2</long><float name="rank">0.9</float><str name="show_transplant_trials">no</str><arr name="sitenames"><str>UT MD Anderson Cancer Center</str></arr><arr name="state"><str>TX</str></arr><str name="study_type">Interventional</str><str name="title">Donor Lymphocyte Infusion for Myeloma</str><arr name="treatment_name"><str>KLH Vaccine</str><str>KLH-id Vaccine</str><str>GM-CSF</str><str>Apheresis</str><str>Donor Lymphocyte Infusion (DLI)</str></arr><str name="weburl">myeloma-donor-lymphocyte-infusion-myeloma</str><arr name="zipcode"><str>77030</str></arr></doc><doc><arr name="conditions"><str>Multiple Myeloma</str></arr><arr name="coordinates"><str>0.00,0.00</str></arr><arr name="criteria"><str>Patients must have a diagnosis of Multiple Myeloma (using the International Myeloma</str><str>Working Group Guidelines)</str><str>Patients must have failed at least one prior treatment regimen containing bortezomib.</str><str>They may be refractory to primary therapy or relapsed and have measurable or assessable</str><str>disease.  (Refractory disease is defined as anything less than PR or progression within 60</str><str>days of completing therapy.)</str><str>Patients with Multiple Myeloma must have measurable active, progressive or</str><str>ymptomatic disease. Measurable disease may be paraprotein or free light chains in</str><str>erum or urine, or the presence of bone marrow plasma cells.</str><str>Age- must be at least 18 years of age.</str><str>Prior therapies may include bendamustine, bortezomib, methylprednisolone, radiation,</str><str>and autologous hematopoietic cell transplant.</str><str>Patients who have received therapy must be at least 4 weeks beyond prior chemotherapy</str><str>(excluding corticosteroids).</str><str>If female patient with reproductive capacity: on effective means of birth control</str><str>during the entire duration of the treatment.</str><str>Patients must have recovered from acute toxicities resulting from therapy</str><str>administered prior to entering this study to grade 1 or less.  Alopecia may not be</str><str>resolved.</str><str>Ability to understand and willingness to sign a written informed consent document.</str><str>Life expectancy of greater than 8 weeks.</str><str>ECOG performance status 0, 1, or 2 (Karnofsky &gt; 60%; see Appendix A).</str><str>Patients must have adequate bone marrow function as defined below:</str><str>absolute neutrophil count &gt; 500/ul platelets &gt; 30,000/ul</str><str>Patients must have adequate liver function as defined below: total bilirubin &lt; 2 times</str><str>the upper limit of normal AST(SGOT), ALT(SGPT) &lt; 3 x upper limit of normal</str><str>Patients must have adequate renal function as defined by a creatinine clearance &gt; 40</str><str>mL/min (measured or estimated by the Cockcroft-Gault formula).</str><str>Patients must have no signs of significant rhabdomyolysis determined by CPK levels</str><str>with a CK &lt; 5 times the upper limit of normal.</str><str>Patients who have not received any chemotherapy treatment for multiple myeloma prior</str><str>to being enrolled in the study.</str><str>Patients who were receiving simvastatin (dose &gt; 40 mg/day), or the equivalent dose of</str><str>another statin) during last prior chemotherapy for multiple myeloma.</str><str>Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering</str><str>the study or those who have not recovered from adverse events due to agents</str><str>administered more than 4 weeks earlier.</str><str>Patients receiving any other investigational agent(s).</str><str>Active second malignancy in the last 5 years except for non-melanoma skin cancer or</str><str>carcinoma-in-situ.</str><str>History of hypersensitivity reactions attributed to simvastatin, bortezomib,</str><str>bendamustine or zoledronic acid.</str><str>Pregnant women are ineligible, as treatment involves unforeseeable risks to the</str><str>embryo or fetus.</str><str>Patients receiving medications that may increase risk of rhabdomyolysis such as</str><str>itraconazole, ketoconazole, erythromycin, cyclosporine, amiodarone, verapamil,</str><str>niacin, HIV protease inhibitors.</str><str>Uncontrolled intercurrent illness including, but not limited to, ongoing or active</str><str>infection, symptomatic congestive heart failure, myopathy, untreated hypothyroidism,</str><str>hereditary myopathy in the family history, unstable angina pectoris, liver disease</str><str>not due to multiple myeloma, cardiac arrhythmia that is symptomatic or not rate</str><str>controlled, active connective tissue disease, active autoimmune disease, or</str><str>psychiatric illness/social situations that would limit compliance with study</str><str>requirements.</str></arr><str name="display_conditions">Myeloma</str><str name="django_ct">txdb.trial</str><str name="django_id">93685</str><str name="gender">Both</str><bool name="has_investigator">true</bool><str name="id">txdb.trial.93685</str><bool name="is_featured">false</bool><bool name="isactive">true</bool><bool name="isusersubmitted">true</bool><date name="lchangetime">2011-04-08T00:00:00Z</date><long name="maxage">100</long><long name="minage">18</long><str name="nctIdentifier">NCT01332617</str><long name="phase">2</long><str name="show_transplant_trials">no</str><arr name="sitenames"><str>James Graham Brown Cancer Center-University of Louisville</str></arr><str name="study_type">Interventional</str><str name="title">Phase II Study of Simvastatin for Relapsed/Refractory Myeloma</str><arr name="treatment_name"><str>Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.</str></arr><str name="weburl">myeloma-phase-ii-study-simvastatin</str><arr name="zipcode"><str>None</str></arr></doc><doc><arr name="conditions"><str>Multiple Myeloma</str><str>Multiple Myeloma and Plasma Cell Neoplasm</str><str>Multiple Myeloma And Immunoproliferative Neoplasms</str><str>Mult Myelm W/O Remission</str><str>Mult Myelm W Remission</str><str>Multiple Myeloma Stage I</str><str>Multiple Myeloma Stage Ii</str><str>Multiple Myeloma Stage Iii</str><str>Fgfr3/Igh Fusion</str><str>Increased Risk For Multiple Myeloma</str><str>Lig4, Ala3val</str><str>Lig4, Thr9ile</str><str>m protein, multiple myeloma</str><str>prevention of multiple myeloma</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; stage ii or higher (for use in a medicare-approved demonstration project)</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; extent of disease unknown, </str><str>whsc1 protein, human</str><str>trappc1 protein, human</str><str>multiple myeloma patients with no documentation of prescribed or received intravenous bisphosphonate therapy</str><str>oncology; disease status; limited to multiple myeloma, systemic disease; smoldering, stage i (for use in a medicare-approved demonstration project)</str><str>myeov protein, human</str><str>Multiple Myeloma Bone Disease</str><str>Refractory Multiple Myeloma</str><str>Hematologic Malignancies, Multiple Myeloma, Lymphoma</str><str>Relapsed or Refractory Multiple Myeloma</str><str>Smoldering Multiple Myeloma</str><str>Relapsed Multiple Myeloma</str><str>Multiple Myeloma With Plasmacytoma</str><str>Relapsed and Refractory Multiple Myeloma</str><str>Hodgkin's Disease or Multiple Myeloma</str><str>Relapsed and/or Refractory Multiple Myeloma</str></arr><arr name="coordinates"><str>0.00,0.00</str></arr><arr name="criteria"><str>Voluntary written informed consent</str><str>Age 18 years or older</str><str>Female subject is either post-menopausal or surgically sterilized or willing to use</str><str>an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine</str><str>device, diaphragm with spermicide, condom with spermicide, or abstinence) for the</str><str>duration of the study.</str><str>Male subject agrees to use an acceptable method for contraception for the duration of</str><str>the study.</str><str>Diagnosis of multiple myeloma based on standard criteria as follows:</str><str>Major Criteria</str><str>Plasmacytomas on tissue biopsy</str><str>Bone marrow plasmacytosis (&gt;30% plasma cells)</str><str>Monoclonal immunoglobulin spike on serum electrophoresis (IgG &gt;3.5 g/dL or IgA</str><str>&gt;2.0 g/dL) or kappa or lambda light chain excretion &gt;1 g/day on 24 hour urine</str><str>protein electrophoresis</str><str>Minor Criteria</str><str>Bone marrow plasmacytosis (10 to 30% plasma cells)</str><str>Monoclonal immunoglobulin present but of lesser magnitude than given under major</str><str>criteria</str><str>Lytic bone lesions</str><str>Normal IgM &lt;50 mg/dL, IgA &lt;100 mg/dL, or IgG &lt;600 mg/dL</str><str>Any of the following sets of criteria will confirm the diagnosis of Multiple</str><str>Myeloma:</str><str>Any two of the major criteria or</str><str>1 major plus 2 minor criteria.</str><str>Measurable disease, defined as a monoclonal immunoglobulin spike (M-Spike) on serum</str><str>electrophoresis of ≥1 g/dL and/or urine monoclonal immunoglobulin spike of ≥200 mg/24</str><str>hours. Non-secretors must have measurable protein by Freelite or measurable disease</str><str>by plasmacytoma to be eligible.</str><str>Patients must have refractory myeloma as defined by a greater than 25% increase in</str><str>their M-protein.  They should have progressed on bortezomib.</str><str>Karnofsky performance status ≥50</str><str>Patients treated with local radiotherapy with or without a brief exposure to steroids</str><str>are eligible.  Patients who require radiotherapy should have entry to the protocol</str><str>deferred until the radiotherapy is completed by at least 4 weeks prior to initiation</str><str>of study drug.</str><str>Meets the following pretreatment laboratory criteria at baseline (Day 1 of Cycle 1,</str><str>before study drug administration)</str><str>Absolute neutrophil count ≥1 x 103/uL</str><str>Platelet count ≥75 x 103/uL</str><str>Hemoglobin ≥8.0 g/dL</str><str>Calculated or measured CrCL ≥ 40 mL/min</str><str>AST or ALT and total bilirubin &lt; 3 x ULN</str><str>Patients meeting any of the following exclusion criteria are not to be registered on</str><str>tudy:</str><str>POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,</str><str>endocrinopathy, monoclonal protein (M-protein) and skin changes)</str><str>Plasma cell leukemia</str><str>Receiving steroids daily for other medical conditions, e.g., asthma, systemic lupus</str><str>erythematosis, rheumatoid arthritis</str><str>Infection not controlled by antibiotics</str><str>HIV infection.  Patients should provide consent for HIV testing according to the</str><str>institution's standard practice.</str><str>Known active hepatitis B or C</str><str>New York Hospital Association (NYHA) Class III or IV heart failure, Echo or MUGA</str><str>ejection fraction &lt; 40% (if known), or EKG evidence of acute ischemic disease</str><str>Other serious medical or psychiatric illness that could potentially interfere with</str><str>the completion of treatment according to this protocol</str><str>Second malignancy requiring treatment in the last 3 years</str><str>Patient has a calculated or measured creatinine clearance of &lt;40 mL/min within 14</str><str>days before enrollment</str><str>Patient has &gt;Grade 2 peripheral neuropathy within 14 days before enrollment</str><str>Patient has hypersensitivity to bortezomib, boron or mannitol and bendamustine</str><str>Positive pregnancy test in women of childbearing potential or subject is pregnant or</str><str>breast-feeding.  Confirmation that the subject is not pregnant must be established by</str><str>a negative serum betaa human chorionic gonadotropin test result obtained during</str><str>creening.  Pregnancy testing is not required for post-menopausal or surgically</str><str>terilized women.</str><str>Patient has received other investigational drugs with 14 days before enrollment</str><str>Serious medical or psychiatric illness likely to interfere with participation in this</str><str>clinical study.</str><str>Diagnosed or treated for another malignancy within 3 years of enrollment, with the</str><str>exception of complete resection of basal cell carcinoma or squamous cell carcinoma of</str><str>the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.</str><str>Voluntary written informed consent</str><str>Age 18 years or older</str><str>Female subject is either post-menopausal or surgically sterilized or willing to use</str><str>an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine</str><str>device, diaphragm with spermicide, condom with spermicide, or abstinence) for the</str><str>duration of the study.</str><str>Male subject agrees to use an acceptable method for contraception for the duration of</str><str>the study.</str><str>Diagnosis of multiple myeloma based on standard criteria as follows:</str><str>Major Criteria</str><str>Plasmacytomas on tissue biopsy</str><str>Bone marrow plasmacytosis (&gt;30% plasma cells)</str><str>Monoclonal immunoglobulin spike on serum electrophoresis (IgG &gt;3.5 g/dL or IgA</str><str>&gt;2.0 g/dL) or kappa or lambda light chain excretion &gt;1 g/day on 24 hour urine</str><str>protein electrophoresis</str><str>Minor Criteria</str><str>Bone marrow plasmacytosis (10 to 30% plasma cells)</str><str>Monoclonal immunoglobulin present but of lesser magnitude than given under major</str><str>criteria</str><str>Lytic bone lesions</str><str>Normal IgM &lt;50 mg/dL, IgA &lt;100 mg/dL, or IgG &lt;600 mg/dL</str><str>Any of the following sets of criteria will confirm the diagnosis of Multiple</str><str>Myeloma:</str><str>Any two of the major criteria or</str><str>1 major plus 2 minor criteria.</str><str>Measurable disease, defined as a monoclonal immunoglobulin spike (M-Spike) on serum</str><str>electrophoresis of ≥1 g/dL and/or urine monoclonal immunoglobulin spike of ≥200 mg/24</str><str>hours. Non-secretors must have measurable protein by Freelite or measurable disease</str><str>by plasmacytoma to be eligible.</str><str>Patients must have refractory myeloma as defined by a greater than 25% increase in</str><str>their M-protein.  They should have progressed on bortezomib.</str><str>Karnofsky performance status ≥50</str><str>Patients treated with local radiotherapy with or without a brief exposure to steroids</str><str>are eligible.  Patients who require radiotherapy should have entry to the protocol</str><str>deferred until the radiotherapy is completed by at least 4 weeks prior to initiation</str><str>of study drug.</str><str>Meets the following pretreatment laboratory criteria at baseline (Day 1 of Cycle 1,</str><str>before study drug administration)</str><str>Absolute neutrophil count ≥1 x 103/uL</str><str>Platelet count ≥75 x 103/uL</str><str>Hemoglobin ≥8.0 g/dL</str><str>Calculated or measured CrCL ≥ 40 mL/min</str><str>AST or ALT and total bilirubin &lt; 3 x ULN</str><str>Patients meeting any of the following exclusion criteria are not to be registered on</str><str>tudy:</str><str>POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,</str><str>endocrinopathy, monoclonal protein (M-protein) and skin changes)</str><str>Plasma cell leukemia</str><str>Receiving steroids daily for other medical conditions, e.g., asthma, systemic lupus</str><str>erythematosis, rheumatoid arthritis</str><str>Infection not controlled by antibiotics</str><str>HIV infection.  Patients should provide consent for HIV testing according to the</str><str>institution's standard practice.</str><str>Known active hepatitis B or C</str><str>New York Hospital Association (NYHA) Class III or IV heart failure, Echo or MUGA</str><str>ejection fraction &lt; 40% (if known), or EKG evidence of acute ischemic disease</str><str>Other serious medical or psychiatric illness that could potentially interfere with</str><str>the completion of treatment according to this protocol</str><str>Second malignancy requiring treatment in the last 3 years</str><str>Patient has a calculated or measured creatinine clearance of &lt;40 mL/min within 14</str><str>days before enrollment</str><str>Patient has &gt;Grade 2 peripheral neuropathy within 14 days before enrollment</str><str>Patient has hypersensitivity to bortezomib, boron or mannitol and bendamustine</str><str>Positive pregnancy test in women of childbearing potential or subject is pregnant or</str><str>breast-feeding.  Confirmation that the subject is not pregnant must be established by</str><str>a negative serum betaa human chorionic gonadotropin test result obtained during</str><str>creening.  Pregnancy testing is not required for post-menopausal or surgically</str><str>terilized women.</str><str>Patient has received other investigational drugs with 14 days before enrollment</str><str>Serious medical or psychiatric illness likely to interfere with participation in this</str><str>clinical study.</str><str>Diagnosed or treated for another malignancy within 3 years of enrollment, with the</str><str>exception of complete resection of basal cell carcinoma or squamous cell carcinoma of</str><str>the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.</str></arr><str name="display_conditions">Multiple Myeloma</str><str name="django_ct">txdb.trial</str><str name="django_id">93673</str><str name="gender">Both</str><bool name="has_investigator">true</bool><str name="id">txdb.trial.93673</str><bool name="is_featured">false</bool><bool name="isactive">true</bool><bool name="isusersubmitted">true</bool><date name="lchangetime">2011-03-14T00:00:00Z</date><long name="maxage">100</long><long name="minage">18</long><str name="nctIdentifier">NCT01315873</str><long name="phase">2</long><str name="show_transplant_trials">no</str><arr name="sitenames"><str>New York University Langone Medical Center</str></arr><str name="study_type">Interventional</str><str name="title">Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma</str><arr name="treatment_name"><str>Bendamustine</str><str>bortezomib</str></arr><str name="weburl">multiple-myeloma-bortezomib-bendamustine-treat-relapsedrefractory</str><arr name="zipcode"><str>None</str></arr></doc><doc><arr name="city"><str>Houston</str></arr><arr name="conditions"><str>Multiple Myeloma</str></arr><arr name="coordinates"><str>29.704584,-95.40466</str></arr><arr name="criteria"><str>Patients with Multiple Myeloma at least 3 months post allogeneic transplant who either</str><str>failed to achieve a complete remission or are relapsing.</str><str>Allograft performed from a related donor who is HLA-compatible (5/6 or 6/6)  or class</str><str>I serologic match and class II molecular matched unrelated donor).</str><str>Zubrod PS&lt;2  life expectancy is not severely limited by concomitant illness.</str><str>Patient willing and able to sign informed consent.</str><str>Patients less than 70 years of age.</str><str>Active CNS disease.</str><str>Uncontrolled acute or chronic GVHD.</str></arr><str name="display_conditions">Multiple Myeloma</str><str name="django_ct">txdb.trial</str><str name="django_id">74757</str><str name="gender">Both</str><bool name="has_investigator">false</bool><str name="id">txdb.trial.74757</str><bool name="is_featured">false</bool><bool name="isactive">false</bool><bool name="isusersubmitted">false</bool><date name="lchangetime">2008-01-09T23:00:00Z</date><long name="maxage">70</long><long name="minage">0</long><str name="nctIdentifier">NCT00504634</str><long name="phase">2</long><str name="show_transplant_trials">no</str><arr name="sitenames"><str>U.T.M.D. Anderson Cancer Center</str></arr><arr name="state"><str>TX</str></arr><str name="study_type">Interventional</str><str name="title">Bortezomib (Velcade) Post Allo for Myeloma</str><arr name="treatment_name"><str>bortezomib</str></arr><str name="weburl">multiple-myeloma-bortezomib-velcade-post-allo</str><arr name="zipcode"><str>77030</str></arr></doc><doc><arr name="city"><str>Little Rock</str></arr><arr name="conditions"><str>Multiple Myeloma</str></arr><arr name="coordinates"><str>34.752391,-92.3355</str></arr><arr name="criteria"><str>Diagnosed with multiple myeloma currently or previously enrolled on UARK 98-026 and</str><str>currently event-free at the time of the evaluation.</str><str>Performance status of 0-2 based of SWOG criteria</str><str>Previously documented platelet count &gt; 75 000/ul within a 35 days prior to enrollment</str><str>Previously documented peripheral absolute neutrophil count &gt;1 000/ul within 35 days</str><str>prior to enrollment.</str><str>Adequate renal function</str><str>Signed informed consent</str><str>Female subject is post-menopausal or willing to use acceptable birth control</str><str>Male subjects agree to use acceptable method of contraceptive</str><str>Hypersensitivity to Bortezomib  boron  or mannitol</str><str>Female subject is pregnant or breastfeeding</str><str>Experienced myocardial infraction within 6 months prior to enrollment</str><str>Received other investigational new drugs within 14 days before enrollment</str><str>Received any anti-myeloma therapy within 14 days</str><str>Serious medical or psychiatric illness likely to interfere with participation in this</str><str>clinical study</str><str>Diagnosed or treated for another malignancy within 3 years of enrollment</str></arr><str name="display_conditions">Multiple Myeloma</str><str name="django_ct">txdb.trial</str><str name="django_id">78726</str><str name="gender">Both</str><bool name="has_investigator">true</bool><str name="id">txdb.trial.78726</str><bool name="is_featured">false</bool><bool name="isactive">false</bool><bool name="isusersubmitted">false</bool><date name="lchangetime">2008-04-10T23:00:00Z</date><long name="maxage">100</long><long name="minage">18</long><str name="nctIdentifier">NCT00657553</str><long name="phase">3</long><float name="rank">0.9250889</float><str name="show_transplant_trials">no</str><arr name="sitenames"><str>University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy</str></arr><arr name="state"><str>AR</str></arr><str name="study_type">Interventional</str><str name="title">Pre-Emptive Strike With Multiple Myeloma Patients</str><arr name="treatment_name"><str>bortezomib</str></arr><arr name="treatment_status"><str>multiple_relapse</str><str>First Relapse</str><str>Second or Multiple relapses</str><str>Refractory</str><str>first_relapse</str></arr><str name="weburl">multiple-myeloma-pre-emptive-strike-multiple-myeloma</str><arr name="zipcode"><str>72205</str></arr></doc><doc><arr name="city"><str>West Hollywood</str><str>Rancho Mirage</str><str>Loma Linda</str><str>Santa Barbara</str><str>Bethesda</str><str>Charlotte</str><str>Dallas</str><str>Duncanville</str><str>Houston</str><str>Provo</str><str>Seattle</str><str>Atlanta</str></arr><arr name="conditions"><str>Multiple Myeloma</str></arr><arr name="coordinates"><str>34.090975,-118.3813</str><str>33.762944,-116.42249</str><str>34.050764,-117.25327</str><str>34.44005,-119.75496</str><str>38.996842,-77.13519</str><str>35.214693,-80.82665</str><str>32.791878,-96.77365</str><str>32.634835,-96.91343</str><str>29.773994,-95.51771</str><str>40.280454,-111.6491</str><str>47.61067,-122.33438</str><str>33.888102,-84.29321</str></arr><arr name="criteria"><str>Patients must fulfill all of the following criteria to be eligible for study</str><str>participation:</str><str>Male or female patients aged ? 18 years old</str><str>Has given voluntary written informed consent before any study-related procedure not</str><str>part of normal medical care  with the understanding that consent may be withdrawn by</str><str>the patient at any time without prejudice to their future medical care</str><str>Previously diagnosed with MM based on standard criteria (12) as follows:</str><str>Major criteria:</str><str>Plasmacytomas on tissue biopsy.</str><str>Bone marrow plasmacytosis (&gt;30% plasma cells).</str><str>Monoclonal immunoglobulin spike on serum electrophoresis IgG &gt;3.5 g/dL or</str><str>IgA &gt;2.0 g/dL; kappa or lambda light chain excretion &gt;1 g/day on 24 hour</str><str>urine protein electrophoresis</str><str>Minor criteria:</str><str>Bone marrow plasmacytosis (10 to 30% plasma cells)</str><str>Monoclonal immunoglobulin present but of lesser magnitude than given 	under</str><str>major criteria</str><str>Lytic bone lesions.</str><str>Normal IgM &lt;50 mg/dL  IgA &lt;100 mg/dL or IgG &lt;600 mg/dL</str><str>Any of the following sets of criteria will confirm the diagnosis of MM:</str><str>Any two of the major criteria</str><str>Major criterion 1 plus minor criterion b  c  or d.</str><str>Major criterion 3 plus minor criterion a or c.</str><str>Minor criteria a  b  and c or a  b  and d.</str><str>Currently has MM with:</str><str>o	Measurable disease  defined as a monoclonal immunoglobulin spike on serum</str><str>electrophoresis of ?1 gm/dL and/or urine monoclonal immunoglobulin spike of ?200 mg/24</str><str>hours  or evidence of lytic bone disease</str><str>ECOG PS ? 2</str><str>Life-expectancy &gt; 3 months</str><str>All women of childbearing potential must use an effective barrier method of</str><str>contraception.  Male patients should use a barrier method of contraception during the</str><str>treatment period and for 3 months thereafter</str><str>Patients must meet the following laboratory criteria at Baseline (Day 1 of Cycle 1</str><str>before study drug administration):</str><str>Platelet count ? 75 x 109/L</str><str>Absolute neutrophil count ? 1.5 x 109/L</str><str>OR if the bone marrow is extensively infiltrated</str><str>Platelet count ? 50 x 109/L</str><str>Absolute neutrophil count ? 1.0 x 109/L</str><str>Patients must meet the following laboratory criteria at the Screening visit conducted</str><str>within 14 days of enrollment (Day 1  Cycle 1):</str><str>AST and ALT ? 3.0 x ULN</str><str>Serum bilirubin ? 2.0 x ULN</str><str>Calculated  or measured creatinine clearance: ?30 mL/minute.  Patient with a</str><str>creatinine &gt;10mL/min and &lt;30 mL/min due to significant myelomatous involvement of</str><str>the kidneys may be enrolled in the study after receipt of approval from the lead</str><str>investigator and sponsor</str><str>Serum potassium ? 3.8 mmol/L</str><str>Serum magnesium &gt;1.8 mg/dL</str><str>Serum phosphorus ? LLN</str><str>Patients are ineligible for entry if any of the following criteria are met:</str><str>Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)</str><str>or thalidomide  lenalidomide  arsenic trioxide  bortezomib  or glucocorticosteroids</str><str>within 3 weeks prior to the first dose of romidepsin</str><str>Prior major surgery within 3 weeks prior to the first day of treatment</str><str>Use of any investigational agent within 4 weeks of study entry</str><str>Prior therapy with romidepsin</str><str>Any known cardiac abnormalities such as:</str><str>Congenital long QT syndrome;</str><str>QTc interval ? 500 milliseconds;</str><str>A myocardial infarction within 12 months of study entry;</str><str>Other significant ECG abnormalities including 2nd atrio-ventricular (AV) block</str><str>type II  3rd degree AV block  or bradycardia (ventricular rate less than 50</str><str>beats/min);</str><str>A history of coronary artery disease (CAD)  e.g.  angina Canadian Class II-IV</str><str>In any patient in whom there is doubt  the patient should have a stress imaging</str><str>study and  if abnormal  angiography to define whether or not CAD is present;</str><str>An ECG recorded at screening showing evidence of cardiac ischemia (ST depression</str><str>depression of ?2 mm  measured from isoelectric line to the ST segment).  If in</str><str>any doubt  the patient should have a stress imaging study and  if abnormal</str><str>angiography to define whether or not CAD is present;</str><str>Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class</str><str>II to IV definitions and/or ejection fraction &lt;40% by MUGA scan or &lt;50% by</str><str>echocardiogram and/or MRI;</str><str>A known history of sustained ventricular tachycardia (VT)  ventricular</str><str>fibrillation (VF)  Torsade de Pointes  or cardiac arrest unless currently</str><str>addressed with an automatic implantable cardioverter defibrillator (AICD);</str><str>Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or</str><str>other causes;</str><str>Uncontrolled hypertension  i.e.  blood pressure (BP) of ?160/95; or</str><str>Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable</str><str>doses of beta-blockers)</str><str>POEMS syndrome (plasma cell dyscrasia with polyneuropathy  organomegaly</str><str>endocrinopathy  monoclonal protein (M-protein) and skin changes</str><str>Plasma cell leukemia</str><str>Primary amyloidosis</str><str>Patients with a prior malignancy within the last 5 years (except for basal or squamous</str><str>cell carcinoma  or in situ cancer of the cervix)</str><str>Severe hypercalcemia  i.e.  serum calcium ?14 mg/dL (3.5 mmol/L)</str><str>Known infection with human immunodeficiency virus (HIV)  hepatitis B  or hepatitis C</str><str>Other concurrent severe and/or uncontrolled medical or psychiatric conditions.</str><str>Concomitant use of drugs that may cause a prolongation of the QTc</str><str>Concomitant use of CYP3A4 inhibitors</str><str>Patients who have hypersensitivity to bortezomib  boron or mannitol</str><str>Patients who are pregnant or breast-feeding</str><str>Patients with any significant history of non-compliance to medical regimens or</str><str>unwilling or unable to comply with the instructions given to him/her by the study</str><str>staff</str></arr><str name="display_conditions">Multiple Myeloma</str><str name="django_ct">txdb.trial</str><str name="django_id">81461</str><str name="gender">Both</str><bool name="has_investigator">true</bool><str name="id">txdb.trial.81461</str><bool name="is_featured">false</bool><bool name="isactive">false</bool><bool name="isusersubmitted">false</bool><date name="lchangetime">2009-11-02T00:00:00Z</date><long name="maxage">100</long><long name="minage">18</long><str name="nctIdentifier">NCT00765102</str><long name="phase">2</long><str name="show_transplant_trials">no</str><arr name="sitenames"><str>James R Berenson, MD, Inc.</str><str>Desert Cancer Care, Inc</str><str>Loma Linda University Cancer Center</str><str>Santa Barbara Hematology Oncology Medical Group, Inc.</str><str>Center for Cancer and Blood Disorders</str><str>Mecklenburg Medical Group</str><str>Baylor Sammons Cancer Center</str><str>Dallas Oncology Consultants, P.A.</str><str>Oncology Consultants, P.A</str><str>Central Utah Clinic, PC</str><str>Virginia Mason Medical Centre</str><str>Georgia Cancer Specialists I, PC</str></arr><arr name="state"><str>CA</str><str>MD</str><str>NC</str><str>TX</str><str>UT</str><str>WA</str><str>GA</str></arr><str name="study_type">Interventional</str><str name="title">Trial of Romidepsin and Bortezomib for Multiple Myeloma</str><arr name="treatment_name"><str>Romidepsin, Bortezomib</str></arr><str name="weburl">multiple-myeloma-trial-romidepsin-bortezomib-multiple</str><arr name="zipcode"><str>90069</str><str>92270</str><str>92354</str><str>93105</str><str>20817</str><str>28204</str><str>75246</str><str>75137</str><str>77024</str><str>84604</str><str>98101</str><str>30341</str></arr></doc></result>
</response>
